NON-PHARMACOLOGICAL TREATMENT OF CHRONIC SYSTOLIC HEART FAILURE : OPTIMIZATIONOF CARDIAC RESYNCHRONIZATION THERAPY FOR THE TREATMENT OF CHRONIC HEART FAILURE: RESPONSE OF PATIENTS AND NEW INDICATIONS by Kosztin, Annamária
NON-PHARMACOLOGICAL TREATMENT OF CHRONIC SYSTOLIC 
HEART FAILURE 
 
OPTIMIZATION OF CARDIAC RESYNCHRONIZATION THERAPY FOR 
THE TREATMENT OF CHRONIC HEART FAILURE: RESPONSE OF 













                           
Supervisors:    Béla Merkely MD, DSc 
  Gábor Földes MD, PhD 
 
Reviewers: Lívia Jánoskúti MD, PhD 
Róbert Pap MD, PhD 
 
Chairman of the Commitee:  Péter Sótonyi MD, DSc 
Members of the Commitee : István Lőrincz MD, PhD 








TABLE OF CONTENTS 
1 ABBREVIATIONS .................................................................................................... 3 
2 INTRODUCTION ...................................................................................................... 5 
2.1 Prevalence and incidence of chronic systolic heart failure ............................................. 5 
2.2 Diagnosis of heart failure ................................................................................................ 5 
1.1.1 Signs and symptoms of heart failure ........................................................................ 5 
2.2.2 Gold standard clinical tools to diagnose heart failure: Echocardiography and NT-
proBNP ................................................................................................................................. 5 
2.3 Treatment of chronic systolic heart failure ..................................................................... 6 
2.3.1 Pharmacological treatment ....................................................................................... 6 
2.3.2 Non-pharmacological treatment: Implantable Cardioverter Defibrillator, Cardiac 
Resynchronization Therapy .................................................................................................. 7 
2.4 Efficacy of cardiac resynchronization therapy ................................................................ 8 
2.4.1 Mechanism of action ................................................................................................ 8 
2.4.2 Current indications ................................................................................................... 9 
2.4.3 Investigation of response: definition of responder patients ..................................... 9 
2.4.4 New indications: .................................................................................................... 16 
3 OBJECTIVES .......................................................................................................... 18 
4 METHODS .............................................................................................................. 19 
4.1 Patient population ......................................................................................................... 19 
4.1.1 Inclusion and exclusion criteria of patients in Part 1. ............................................ 19 
4.1.2 Patient population and randomization in BUDAPEST CRT upgrade study .......... 20 
4.2 Follow up and investigations ........................................................................................ 22 
4.2.1 Follow up ............................................................................................................... 22 
4.2.2 ECG ....................................................................................................................... 23 
4.2.3 Echocardiography .................................................................................................. 24 
4.2.4 Serum biomarker measurements ............................................................................ 26 
4.3 Device implantation and programming ........................................................................ 26 
4.3.1 Device implantation procedure in Part 1................................................................ 26 
4.3.2 Upgrade procedure in BUDAPEST CRT UPGRADE study ................................. 26 
4.3.3 RV-LV AD measurement at implantations ............................................................ 28 
4.3.4 Device programming during BUDAPEST CRT UPGRADE study ...................... 29 
4.4 Endpoints ...................................................................................................................... 29 
4.4.1 Endpoints of Part 1................................................................................................. 29 
4.4.2 Endpoints of Part 2................................................................................................. 31 
DOI:10.14753/SE.2017.2351
 2 
4.5 Statistics and methods for analyses ............................................................................... 31 
4.5.1 Statistical analysis .................................................................................................. 31 
4.5.2 Study selection for systematic review and meta-analyses ..................................... 32 
4.5.3 Sample size calculation and statistical methods in the BUDAPEST CRT 
UPGRADE study................................................................................................................ 35 
5 RESULTS ................................................................................................................ 36 
5.1 Part 1 – Optimization of patient selection and intraoperative techniques in order to 
achieve a more beneficial clinical response ............................................................................ 36 
5.1.1 Optimal patient selection by measuring NT-proBNP and a novel biomarker, serum 
CT-apelin ............................................................................................................................ 36 
5.1.2 The role of an intraoperative parameter, the RV-LV AD measuring during CRT 
implantation ........................................................................................................................ 45 
5.2 Part 2 - The question of CRT upgrade .......................................................................... 60 
5.2.1 A systematic review and meta-analyses from the literature about the outcome of 
patients after CRT upgrade vs. de novo CRT implantation ................................................ 60 
5.2.2 Current status and preliminary results of the  
BUDAPEST CRT upgrade study ....................................................................................... 79 
6 DISCUSSION .......................................................................................................... 84 
6.1 Optimization of patient selection and intraoperative techniques in order to achieve a 
beneficial clinical response after CRT implantation ............................................................... 84 
6.2 Part 2 - The question of CRT upgrade .......................................................................... 88 
6.3 Limitations .................................................................................................................... 97 
7 CONCLUSIONS ...................................................................................................... 99 
8 SUMMARY ........................................................................................................... 102 
9 ÖSSZEFOGLALÁS ............................................................................................... 103 
10 REFERENCES .................................................................................................... 104 
11 PUBLICATIONS ................................................................................................. 124 







ACE: Angiotensin Converting Enzyme  
AE: Adverse Event 
ARB:  Angiotensin Receptor Blocker 
AV: Atrio-Ventricular 
AUC: Area Under the Curve 
BNP: Brain Natriuretic Peptide 
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EDV: End-diastolic Volume 
EF: Ejection Fraction 
ELISA: Enzyme-linked Immunosorbent Assay 
ESV: End-systolic Volume 
EDV: End-diastolic Volume 
HF: Heart Failure 
HR: Heart Rate 
HTX: Heart Transplantation 
ICD: Implantable Cardioverter Defibrillator 
IQR: Interquartile Range 
IVCD: Intraventricular Conduction Disorder 
LBBB: Left Bundle Branch Block 
LVEF: Left Ventricular Ejection Fraction 
LVESV: Left Ventricular End-systolic Volume 
NYHA: New York Heart Association 
NT-proBNP: N-terminal prohormone Brain Natriuretic Peptide 




PI: Principal Investigator 
PTX: Pneumothorax 
ROC: Receiver Operating Characteristic Curve 
RBBB: Right Bundle Branch Block 
RVAP: Right Ventricular Apical Pacing 
RV-LV AD: Right to Left Ventricular Activation Delay 
SAE: Serious Adverse Event, 
TDI: Tissue Doppler Imaging 
UADE: Unanticipated Adverse Device Effect 
USADE: Unanticipated Serious Adverse Device Effect 
VT: Ventricular Tachycardia 
VF: Ventricular Fibrillation 
VV: Ventriculo-Ventricular 
6MWT: 6-minute Walk Test 








2.1 Prevalence and incidence of chronic systolic heart failure 
 
During the past half century, cardiovascular disease has become the largest cause of 
mortality worldwide (1), the prevalence is approximately 1–2% of the adult population in 
developed countries, rising to ≥10% among people over 70 years of age (2). Heart failure 
(HF) is still a major and rising healthcare problem, due to the successful acute coronary 
syndrome-treatment and ageing, the previously fatal condition turned to a prolonged 
chronic disease with subsequent hospital admissions (1). Based on data about causes of 
cardiovascular hospitalization suggests, the ratio of HF hospitalization is decreasing, but 
primarily in the population with reduced, not with preserved ejection fraction (2). The 
European Society of Cardiology Heart Failure Registry, where approximately 70% of 
patients had reduced ejection fraction (<45%), showed that 12-month all-cause mortality 
rates for hospitalized and ambulatory patients were 17% and 7%, respectively (3), while 
the 12-month hospitalization rates were 44% and 32%, respectively (3).  
 
2.2 Diagnosis of heart failure 
1.1.1 Signs and symptoms of heart failure 
 
Heart failure is a complex clinical syndrome with non-specific signs and symptoms of 
fluid retention and increased sympathetic activity (2), therefor the most accurate 
diagnostic tools of HF are supposed to provide objective evidences of a structural or 
functional cardiac abnormality (2). 
 
2.2.2 Gold standard clinical tools to diagnose heart failure: Echocardiography and 
NT-proBNP 
 
Echocardiography is the most useful, widely available and easily reproducible test to 
confirm the diagnosis of HF. It provides immediate information on ejection fraction, 
systolic and diastolic function, chamber volumes and dimensions and valve function, 
which are essential for the diagnosis and treatment of HF (2). 
The other gold standard diagnostic tool is the B-type natriuretic peptide (BNP) and N-
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terminal prohormone BNP (NT-proBNP), which is broken down by an enzyme called 
neprilysin. The negative predictive values of these peptides are very similar and high 
(0.94–0.98) during the chronic and acute HF events, however the positive predictive 
values are lower in chronic (0.44–0.57) and in acute settings (0.66–0.67) as well (4).  
Therefor the evaluation of natriuretic peptides is primarily recommended for excluding, 
not for confirming the diagnosis of HF. 
 
2.3 Treatment of chronic systolic heart failure 
2.3.1 Pharmacological treatment 
 
In patients with chronic systolic HF the aim of the treatment includes the improvement 
of their symptoms and quality of life, decrease the number and duration of hospital 
admissions and reduce mortality. By evidences of high-volume, randomized trials, the 
basic pharmacological regime has been confirmed as the most effective therapy which 
improves these endpoints.  
Groups of neurohormonal antagonists reduce all-cause mortality, thus present as IA 
evidence level in the current guidelines: these are the beta blockers, ACE inhibitors and 
Mineralocorticoid Receptor Antagonists (2). However a new compound, CLCZ 
(combination of ARB and the neprilysin inhibitor, sacubitril) has been already shown to 
be superior to an ACE inhibitor, enalapril (2). Until further evidences are coming, it is 
recommended as a IB-drug for replacement of an ACE-inhibitor in ambulatory patients 
with systolic HF who remain symptomatic despite optimal medical treatment. 
Angiotensin Receptor Blockers are alternative therapies when ACE inhibitors are 
contraindicated or not tolerated. Any other pharmacological treatments such as diuretics, 
ivabradine, direct vasodilators and digoxin can be added for selected patient populations 




2.3.2 Non-pharmacological treatment: Implantable Cardioverter Defibrillator (ICD), 
Cardiac Resynchronization Therapy (CRT) 
 
2.3.2.1 Implantable Cardioverter Defibrillator  
A high proportion of deaths among patients with severe systolic HF occur suddenly and 
unexpectedly due to electrical disturbances, including ventricular arrhythmias, 
bradycardia or asystole (2). We can account approximately 20% of incidence of sudden 
cardiac death in patients with  lower than 30% of left ventricular ejection fraction (5). To 
prevent sudden cardiac death and to terminate potentially lethal ventricular arrhythmias, 
the most effective therapy is the implantable cardioverter defibrillator compared to 
antiarrhythmic agents.  
As a choice of secondary prevention, ICD was investigated in AVID(6), CIDS(7),  and 
CASH(8) trials, where ischemic and non-ischemic patients were enrolled after ventricular 
tachycardia (VT) or ventricular fibrillation (VF) with syncope and low ejection fraction 
(except for CASH trial, where the mean ejection fraction was 46 ± 18%). In these trials 
ICD was compared to amiodarone, sotalol, metoprolol or propafenon. Each trials 
confirmed that ICD group experienced 20-31% relative risk reduction in all-cause 
mortality in the first three years compared to groups treated with antiarrhytmic agents.  
For primary prevention MADIT I (9), MADIT II (10), MUSTT  (11) and SCAD-HeFT 
(12) trials confirmed the effectivity of ICD compared to conventional therapy. The first, 
MADIT I trial investigated ischemic HF patients with mild to moderate symptoms 
(NYHA I-III) with inducible or asymptomatic VT and low ejection fraction. The ICD 
group experienced a 31% risk reduction in all-cause mortality, while on conventional 
treatment arm 22% risk reduction was observed during the mean follow up time of 27 
months. In MADIT II  1232 patients were enrolled who experienced a myocardial 
infarction less than 30 days prior to enrolment and had low EF (≤30%) and they were 
randomized to ICD or non-ICD arm in a 3:2 manner. The study ended with similarly 
favourable results as MADIT I.  
SCD-HeFT (12) was the latest of those studies demonstrating the benefits of ICDs. In the 
trial 2521 mild to moderate HF patients (NYHA II-III) with low EF (≤35%) were 
investigated. The results concluded the evidences of studies mentioned above,  that ICDs 
significantly reduce the risk of all-cause mortality (from 31 to 55%) in groups suffering 




Thus by the current guidelines (2) patients have to be implanted an ICD after 3 months 
of optimal medical treatment with ≤35% ejection fraction and symptomatic HF (NYHA 
II-IV functional class) with narrow QRS <120ms in primary prevention. In secondary 
prevention survivors of sudden cardiac death or patients who have experienced sustained 
symptomatic ventricular arrhythmias should be implanted an ICD. In the decision of 
performing the implantation we should take into consideration the candidate’s co-
morbidities, etiology, quality of life, the left ventricular ejection fraction and the expected 
survival over the following year.(2) 
 
2.3.2.2 Cardiac Resynchronization Therapy  
While the ICD reduces only the risk of sudden cardiac death, CRT has been shown to 
improve cardiac function, HF symptoms, and to reduce hospitalization and all-cause 
mortality in patients with mild to severe HF and a prolonged QRS (13-15). By implanting 
an additional left ventricular lead into a side branch of the coronary sinus or  by surgical 
or transseptal technique to the left ventricle directly,  it is possible to pace both ventricles  
simultaneously resolving the intra- and interventricular electromechanical delay.  
 
2.4 Efficacy of cardiac resynchronization therapy 
2.4.1 Mechanism of action  
 
Due to the progression of the disease, conduction delay - manifested as prolonged QRS - 
is frequent in HF patients and associated with increased prevalence of mechanical 
dyssynchrony. Primarily by pacing along the latest activated part of the left ventricle 
simultaneously with the right ventricle, results in a better activation pattern.  The impact 
of decreasing the interventicular dyssynchony might be less valuable, by the diminishing 
of intraventricular dyssynchrony of the left ventricle could CRT mostly exert its 
beneficial effect. 
Secondarily CRT devices with atrial electrodes also allow the optimization of the 
atrioventricular interval for patients with sinus rhythm, which produces a better filling 
time. 
The acute haemodynamic and electromechanical effect can be observed in the increasing 
DOI:10.14753/SE.2017.2351
 9 
stroke volume, decreasing mitral regurgitation, pulmonary wedge pressure and narrowing 
QRS. These actions turn to reverse remodeling which is expressed from cellular to 
morphological levels, and it is reflected in the beneficial long-term outcome such as 
reduced mortality and HF hospitalization.  
 
2.4.2 Current indications 
 
There is a conclusive evidence of short- and long-term effect of CRT on symptoms, 
exercise capacity, left ventricular function and reduced HF hospitalization and all-cause 
mortality in symptomatic patients (NYHA II-IV functional class) with sinus rhythm and 
typical LBBB morphology and wide QRS (>150ms). In this patient population, CRT 
implantation is recommended with IA evidence level. In those patients, whom QRS is 
between 120-150 ms with Left Bundle Branch Block (LBBB) morphology, the evidence 
level is B (16). 
The benefit in those, whose non-typical LBBB is less pronounced, thus those with wide 
QRS >150ms, IIa class B level, while in those patients who has QRS of 120-150 ms, CRT 
is less recommended as IIb class B evidence  level. CRT is not recommended in patients 
with narrow QRS, Class III. (16). 
 
2.4.3 Investigation of response: definition of responder patients 
 
The definition of responder patients is primarily based on echocardiographic parameters, 
since improvement of left ventricular ejection fraction and left ventricular dimensions are 
strongly correlated with the clinical outcome and proved to be surrogate endpoints of 
respond (17). However there has been a mild heterogeneity in defining response to CRT, 
based on the most frequently used end-systolic volume (ESV) reduction, patients can be 
classified as super responders (≥30% ESV decrease), responders (30-15% ESV decrease), 
non-responders (<15% ESV decrease) and negative responders (ESV increase)(18). 
Defining responder criteria also involve functional parameters in some studies such as 
NYHA class, 6 minute walk test or quality of life questionnaires, which show less 
comprehensive results in detecting the positive response to CRT (19). Besides there have 
been some additional parameters such as detection of the decrease of functional mitral 
regurgitation or septal dyskinesis (20,21) which might also reflect the beneficial response 
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(2) to the therapy. 
Based on the definitions mentioned above, approximately 22% of patients are super-
responders, further 35% are responders, while 43% response less favorably to CRT (non-
responders or negative responders)(18). Mainly patients with non-ischemic etiology, 
women and patients with typical LBBB morphology seem to be the most optimal 
candidates (2).  
 
2.4.3.1 Before CRT implantation - optimal patient selection   
  
2.4.3.1.1 QRS width and morphology 
 
The prognostic implications of QRS width and morphology are between the main 
predictors of  long-term outcome after CRT implantation although partly still debated. 
However either the early haemodynamic, echocardiographic investigations or 
randomized trials confirmed the poor response to CRT in patients with QRS<150ms, the 
first recommendations of ESC guidelines were derived from the inclusion criteria of two 
initial high-volume randomized studies, the COMPANION(22) and CARE-HF(23) 
studies, which used QRS>120ms. Although 130 or 150 ms cut off values also appeared 
in some trials (MUSTIC(24) or MIRACLE(25)),  the initial 120 ms was accepted 
continuously year after year. The findings of MADIT CRT (21) were incorporated in the 
guidelines as the next milestones, confirming patients with mild symptoms also benefit 
from CRT over 150 ms QRS duration. While most of the clinical trials and meta-analyses 
suggest a moderate clinical improvement to CRT between 120-150 ms QRS regardless 
of symptoms, there are limited and controversial data for echocardiographic 
dyssynchrony parameters, which may additionally help to appoint responder patients in 
this grey zone (26). 
Beside the QRS duration, the morphology is also a crucial parameter. The sub-study of 
MADIT-CRT(25) showed that the presence of LBBB morphology was associated with 
53% reduction in the risk of all-cause mortality and HF events, while patients with non-
LBBB morphology did not show any clinical benefit to CRT. These findings were also 
confirmed by recent meta-analyses, which showed 36% and 24% risk reduction in all-
cause mortality in patients with LBBB, whereas no clinical benefit could be observed in 
non-LBBB respectively(27). However regarding to a recent meta-analysis from Cleland 
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et al., the impact of QRS morphology is still questionable, while only QRS duration 
predicted the magnitude of the effect of CRT on outcomes.(28) 
The 2013 ESC guideline provides IA evidence level for NYHA II-IVa patients with QRS 
>150ms and IB with QRS 120-150 ms and LBBB morphology, while III B for narrow 
QRS (<120ms).  
 
2.4.3.1.2 Ejection fraction 
 
Left ventricular ejection fraction (LVEF) is one of the basic parameters that determine 
the selection of patients for resynchronization, while the baseline value and its 
improvement strongly correlate with the outcome, thus regards as a surrogate endpoint in 
chronic systolic HF (29).  
The first large randomized trials – COMPANION (22) and CARE HF(23) included 
patients with LVEF≤ 35% and NYHA III-IV functional class. Their findings were 
conclusive in this severely symptomatic patient population, less than 35% patients had a 
clear benefit from resynchronization. Further studies with higher inclusion criteria for EF 
and mild symptoms were also designed. In the REVERSE(30) trial patients with ≤40% 
of EF were included. Based on the core lab measurements,  approximately 30% of the 
patients had >30% EF, which population also showed a significant improvement in 
echocardiographic parameters and composite clinical endpoint of HF events and all-cause 
mortality.  
In the MADIT-CRT trial(31) despite the inclusion criteria of ≤30%  LVEF, patients with 
higher ejection fraction were also enrolled assessed by the core lab. Kutyifa et al. found 
the beneficial effect of CRT could be detected regardless of ejection fraction, moreover 
patients with higher than 30% of LVEF showed the largest echocardiographic reverse 
remodeling (31). Based on the results of previous trials, the current guidelines recommend 
CRT for patients with LVEF ≤ 35% and NYHA II-IVa. 
However the role of right ventricular function improvement after CRT is less evaluated 
and described in the literature, there have been evidences about a more favourable clinical 
outcome and long-term results in those patients who has a better baseline right ventricular 
function assessed by sophisticated parameters such as longitudinal and global strain (32). 
2.4.3.1.3 Symptoms 
 
There is a clear evidence for device implantation in patients with mild to severe symptoms 
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(NYHA II-IVa). The first randomized trials included patients with severe symptoms 
(NYHA III-IV), thereafter MADIT-CRT(21), REVERSE(33) ad RAFT(33) trials 
supported the benefits of CRT in mildly symptomatic patients. Based on MADIT-
CRT(21) and REVERSE(33), where 18% and 15% of included patients were 
asymptomatic - NYHA I respectively, the trials confirmed that CRT did not reduce all-
cause mortality or HF events in this patient population. In NYHA II, MADIT-CRT long 
term follow up results showed 35% risk reduction in patients in NYHA II functional class 
with ischemic etiology, while 43% risk reduction could be observed in the composite 
primary endpoint in non-ischemic patients compared to ICD alone patients (34). In a 
recent meta-analysis Al Majed et al. found that CRT reduces the risk of all-cause mortality 
and HF hospitalization in patients with NYHA I-II 29% and 17% respectively, which is 
comparable to patients with severe symptoms, NYHA III-IVa as well(35). 
 
2.4.3.1.4 Predictors of response – biomarkers, CT-apelin 
 
An optimal biomarker in chronic HF should be specific enough to detect the disease, 
provide an estimation of the prognosis and guide the treatment. The gold standard HF 
biomarker is the NT-proBNP. However, in patients who underwent CRT implantation, 
the cross-sectional values are suitable for describing the current status of the patient but 
prior studies failed to confirm its role as an independent predictor of response to CRT 
(36,37).  Thus novel biomarkers are being investigated, in which inflammatory factors 
can take a part. Due to the low cardiac output and relating hypoperfusion all over the 
body, a systematic inflammation can occur during chronic HF. By activating the 
complement system, its components such as C3a might have an important role and has a 
predictive value for the response to CRT (38): elevated C3a levels increase the risk of 
mortality independent of the NT- proBNP levels, while CRT has an anti-inflammatoric 
effect by reducing the complement activation, thus measuring of the alteration of C3a 
might be a potential biomarker in the future. There are some other routinely measured 
laboratory parameters, which might help tailoring the therapy and predict the outcome 
after CRT implantation. Based on the above mentioned immuno-pathophysiology, the 
ratio of neutrophil leukocytes to the lymphocytes (39) or due to the congestion, the red 
blood cell distribution width might be novel prognostic markers in chronic HF (40). From 
the state-of-art HF biomarkers such as galectin-3, copeptin, NGAL, adrenomedullin or 
apelin (41,42), the latter has been emerged as a promising biomarker and investigated 
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comprehensively. Pre-pro-Apelin is expressed as a pro-hormone from several tissues. The 
apelin and its G-coupled receptor are expressed early during the embryonic development 
of the heart and affect the angiogenesis and maturation of cardiovascular cells (43). Its 
expression is also detected in adults where apelin has a paracrine effect as one of the most 
potent stimulators of cardiac contractility (44), moreover acts as a mediator of blood 
pressure via nitric-oxide dependent pathways (45). However, the role of apelin in HF is 
still unclear as changes of plasma levels are controversial in humans during the 
progression of HF (46-48). In addition, no data was available on its value in predicting or 
evaluating the response to CRT until now. 
 
2.4.3.2 During the implantation       
  
2.4.3.2.1 The role of intra- and interventricular delay  
 
During the progression of HF, prolonged atrio-ventricular (AV) and ventriculo-
ventricular (VV) delay can be observed. Interventricular dyssynchrony refers to 
prolonged activation between the ventricles, while intraventricular dyssynchrony 
develops by the late activation of mostly the postero-lateral / lateral region of the left 
ventricle (49). Several studies tested imaging (transthoracal echocardiography and MRI) 
and electrophysiological techniques to assess the localization and the role of intra- and 
interventricular dyssynchrony in CRT response.  
The echocardiographic evaluation of interventricular dyssynchrony is based on the delay 
between the beginning of aortic and pulmonary velocity curves and the QRS, over 40ms 
delay the dyssynchrony can be confirmed. Intraventricular dyssynchrony can be 
evaluated by TDI or speckle tracking methods by segments, the latest activated part 
should contract with at least 50ms delay (49). These methods reflect primarily the 
mechanical dyssynchrony, thus there might have been differences between dyssynchrony 
assessed by echocardiogaphic or electrophysiological techniques.  
The electroanatomical mapping is a more precise technique, imaging the electrical 
activation pattern directly (50). In this regard the most often investigated phenomenon is 
LBBB. Auricchio et al. (50) found that an U-shaped pattern of activation can be observed, 
where the line of block generally paralleled the septum.  
Regardless of the method, the assessment of the latest activated part in the left ventricle 
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could be essential in order to perform a guided left ventricular lead implantation, thus 
achieve a better clinical response to CRT. 
 
2.4.3.2.2 Targeting of the LV lead implantation 
 
It has been proposed that optimal LV lead placement is an important determinant of 
response to CRT. The location of the left and right ventricular leads affects clinical 
outcome, and the incidence of ventricular tachyarrythmias (51). There have been positive 
results for echocardiography-guided left ventricular lead implantation. Those who were 
randomized to planned lead implantation by evaluating the latest site of peak contraction 
by strain analyses, yielded 15% higher amount of echocardiographic responder patients 
(52). 
Furthermore, few smaller studies have indicated that the electrical delay between the 
signals sensed by the LV lead and the beginning of QRS duration (Q-LV), or the distance 
between the electrical signals of the left and right ventricular leads (RV-LV AD) predicted 
echocardiographic improvement and clinical outcome (53-55).   
By measuring LV lead activation time from the beginning of the QRS (Q-LV), Gold et 
al. showed significant increase in functional and echocardiographic improvement in those 
patients who had greater Q-LV time.  
RV-LV activation delay may also reflect the distance of RV and LV leads, moreover 
shows the electrical dyssynchrony and prolonged activation pattern derived from the slow 
conduction due to e.g. a scar tissue. Those studies, which used RV-LV activation delay 
(55,56), also showed significant improvement in echocardiographic response and in 
clinical outcome in patients with longer measured activation delay. However, none of 
these studies looked specifically at sub-groups of LBBB and non-LBBB patients. 
Based on these prior studies the assessment the RV-LV delay during the implantation 




2.4.3.2.3 Multipolar pacing 
 
However in novel therapeutic attempts multiple right and left ventricular stimulations are 
performed by multiple leads, in the recent thesis we are focusing on the comparison of 
bipolar and quadripolar left ventricular pacing.  
During the implantation procedure, it can happen that only suboptimal target vein can be 
found for LV lead implantation or difficult to avoid phrenic nerve stimulation. By using 
multipolar pacing, a better clinical response and lower number of phrenic nerve 
stimulation (57) can be observed. Several investigations (58-60) confirmed a more 
pronounced improvement by quadripolar lead implantation and optimization of the 
pacing site compared to bipolar stimulation. This effect was reflected either in 
haemodynamic (58,60) or echocardiographic response (59). 
 
2.4.3.3 Follow up - patient management and device optimization   
  
2.4.3.3.1 AV and VV delay 
 
The proper programming of the device such as AV and VV delay seems slightly 
controversial, while prior studies (61,62) found that it has an impact on better response to 
CRT. However large randomized trials (63,64) could not confirm these data, therefor in 
the current guidelines, it is not recommended routinely, but supported to use in non-
responder patients (65). 
The optimization is classified into two groups: echocardiography-based and device-
specific measurements and settings. Regarding the AV delay, a suboptimal AV 
programming can result in a 10-15% decrease in cardiac output. The optimal setting was 
investigated by a large randomized trial (63), where no difference was found in the 
echocardiographic response in cases of fix 120ms AV delay, echocardiographic 
optimization or a device-specific optimization (SMART AV function).  
The VV delay optimization can also be controlled by echocardiography-based higher 
stroke volume, ECG-based QRS narrowing or device-specific programs. However, these 




2.4.3.3.2 Remote monitoring 
 
Remote monitoring is presented as IIa A evidence in the current ESC guidelines (65). By 
home monitoring it is considered to detect the arrhythmias or technical issues earlier, 
moreover HF hospitalizations or malignant arrhythmias can be prevented (66,67).  
 
2.4.4 New indications:        
  
2.4.4.1 Non-Left Bundle Branch Block morphology 
Recent studies have suggested that patients with LBBB derive a significant benefit from 
CRT implantation, while in patients with a non-LBBB (as Right Bundle Branch Block - 
RBBB or intraventricular conduction delay - IVCD) the benefit is less if at all discernible 
(68,69). In non-LBBB patients with a prolonged PR interval, resynchronization with ICD 
treatment (CRT-D) was also associated with a 73% reduction in the risk of heart 
failure/death and 81% decrease in the risk of all-cause mortality compared with 
implantable cardioverter defibrillator therapy without CRT (70). In non-LBBB patients 
with normal PR, CRT-D therapy was associated with a trend toward an increased risk of 
heart failure/death (HR 1.45; 95%, CI 0.96-2.19; P=0.078; P<0.001) and a more than 2-
fold higher mortality (HR 2.14; 95%, CI 1.12-4.09; P=0.022; P<0.001) compared with 
implantable cardioverter defibrillator therapy without CRT(70). 
 
2.4.4.2 Upgrading to Cardiac Resynchronization Therapy    
  
2.4.4.2.1 Lack of evidences  
 
Since chronic right ventricular pacing is thought to be deleterious by increasing the risk 
of atrial fibrillation, HF and all-cause mortality (71,72), patients already carrying 
conventional pacemaker (PM) or ICD systems are often considered for upgrading to CRT. 
Recent studies have suggested that only patients with typical LBBB ECG morphology 
derive a significant benefit from CRT(68,69). Although right ventricular pacing could 
reveal ventricular dyssynchrony similar to LBBB, data are scarce regarding the benefit of 
upgrade CRT in patients with previously implanted cardiac pacemaker or ICD systems.   
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The latest ESC guidelines on cardiac pacing and resynchronization therapy recommended 
CRT upgrade as a class I indication (level B) for symptomatic patients (NYHA III-IV) 
with low ejection fraction (LVEF≤35%)(65), while the most recent European heart failure 
guidelines restrict this indication as a class IIb (level B)(2). The ACC guidelines focused 
on the percentage of pacing rather than symptoms. 
 
2.4.4.2.2 The BUDAPEST CRT upgrade study  
 
About 28% of CRT implantations in Europe are upgrade procedures after previously 
implanted cardiac devices(73). To date, there are no conclusive results on the outcome of 
patients who underwent CRT-D upgrade from having previously implanted pacemaker 
or ICD devices, symptomatic HF, reduced ejection fraction and relatively high percentage 
(>20%) ventricular pacing. Furthermore, recent data indicate that upgrade procedures to 
biventricular pacing are associated with a relatively high complication rate (74), 
suggesting that a large, multicenter, randomized trial is required. We have designed an 
investigator initiated, prospective, randomized, multicenter trial, the BUDAPEST CRT 
upgrade study to clarify the question with 21 European and Israeli sites’ participation. 
The study is conducted in accordance with the Helsinki Declaration, the Good Clinical 





Our aim was to determine novel parameters that might improve the clinical outcome after 
CRT implantation in regard of optimal patient selection and special methods during the 
implantation or early detection of response.  
In order to optimize the patient selection and early assessment of the response to CRT, 
the serum levels of a novel biomarker, CT-apelin were measured. Its predictive value for 
the echocardiographic response was investigated and compared to the gold standard NT-
proBNP levels  at baseline and 6 months after resynchronization. 
Moreover we examined the impact of an easily measured parameter during the 
implantation, the RV-LV activation delay. Its predictive role in the functional, 
echocardiographic and clinical outcome such as heart failure, all-cause mortality or 
laboratory parameters including NT-proBNP and renal function was assessed by the 
baseline QRS morphology of patients who underwent CRT implantation.  
We would also focus on those questions, which are not entirely covered by the current 
ESC guidelines: patients who have an already implanted conventional pacemaker or ICD 
and referred to CRT upgrade. By concluding the available evidences of the literature, we 
analysed the clinical outcome, adverse events and long-term survival after upgrading 
compared to de novo implantation. However conclusive data will be provided by the 
BUDAPEST-CRT Upgrade Study, which investigates the all-cause mortality, heart 
failure events and echocardiographic response as primary endpoint besides functional 
response and safety after 12 months. In the current thesis the actual status, rationale and 






4 METHODS  
 
For a better interpretation, those studies in which optimal patients selection and 
intraoperative parameters were evaluated, are shown separately (Part 1) in the Methods 
and Results sections. In Part 2 the questions of CRT upgrade are shown by concluding 
the results of the currently available data in the literature in a meta-analysis and  the 
rationale and status of the BUDAPEST CRT upgrade study. 
 
4.1 Patient population 
4.1.1 Inclusion and exclusion criteria of patients in Part 1. 
 
Between September 2009 and December 2010 a prospective, observational, cohort study 
was designed to investigate patients undergoing successful CRT implantation at the Heart 
and Vascular Center, Semmelweis University, Budapest, Hungary. Patients with both 
ischemic and non-ischemic etiology were enrolled. Inclusion criteria were low left 
ventricular ejection fraction (EF≤35%), a prolonged baseline QRS interval (≥120 ms) and 
symptoms of HF (NYHA II-IVa functional class) despite optimal medical treatment. 
Before the enrolment all patients underwent diagnostic coronarography or 
recoronarography in order to tailor the implantation by images of coronary sinus, 
moreover atherosclerosis as a secondary cause of HF could be verified. In those cases, 
where a percutaneous coronary intervention (PCI) was performed, patients were enrolled 
after 3 months of the procedure. 
Exclusion criteria were patients with genetic HF, known malignant or inflammatory 
disease or severely reduced life expectancy, less than 1 year. We did not include those 
patients who were geographically unstable, or unwilling to attend regular follow ups or 
did not consent to the study.  
In the investigation of optimal patient selection by serum biomarker measurements, from 
the total included patient cohort those who died before 6 month-follow up or unable or 
unwilling to give serum samples for biomarker assessments were censored due to the lack 
of ability to classify them according to response criteria and further biomarker 
measurements. Therefor it can be viewed as a substudy in the current thesis. 
The study was approved by the Institutional Scientific Ethics Committee. All patients 




4.1.2 Patient population and randomization in BUDAPEST CRT upgrade study 
 
This prospective, multicenter, randomized trial was prepared and designed in 2013 by the 
principal investigator (PI), Professor Bela Merkely, co-PIs as Dr. Valentina Kutyifa and 
Professor Ilan Goldenberg and members of Steering Committee. High-volume, 
experienced centers were contacted in Europe and Israel, each sites which would 
participate got the opportunity to enroll patients after contracting and initiation. 
From November 2014 patients are enrolled to the study regardless of the HF etiology with 
reduced LVEF (≤ 35%), symptoms (NYHA functional class II-IVa) despite optimal 
medical treatment with single or dual chamber pacemakers or ICD devices implanted at 
least 6 months before the inclusion (with ≥20% RV pacing over 90 days prior to 
enrolment and wide paced QRS duration ≥150 ms) with sinus rhythm, atrial 
fibrillation/flutter or atrial tachycardia as per protocol. The rate or frequency or rhythm 
control management is based on the physician’s discretion. Patients are excluded with 
typical LBBB intrinsic QRS morphology, severe right ventricular dilatation (>50mm), 
severe renal disease (serum creatinine >200umol/l) or other co-morbidities, which might 
influence the outcome of the patient. Those who had acute events (e.g. PCI, myocarditis, 
Coronary Artery Bypass Graft - CABG) or in those cases where heart transplantation 
(HTX) is planned. Detailed inclusion and exclusion criteria are listed in Table 1.   
In the Semmelweis University after physicians pre-screened their patients and those who 
are thought to be eligible for the study, are referred to Annamaria Kosztin for screening 
and consent.  
Those subjects, who proved to be eligible for the study, could be randomized in a 3:2 






Table 1. Inclusion and exclusion criteria of the BUDAPEST CRT upgrade study 
Inclusion criteria Exclusion criteria 
1. Age: over 18 years 
2. Cardiomyopathy with LVEF ≤35%, 
ischemic or non-ischemic 
3. Single or dual chamber PM or ICD 
implanted ≥6 months prior to 
enrolment (battery depletion or 
another indication for upgrade is not 
required) 
4. RV pacing ≥20% in the prior ≥90 
days (use of algorithms to avoid 
ventricular pacing is recommended, 
per discretion of the clinician) 
5. Paced QRS duration  ≥150 ms 
6. Symptomatic heart failure with 
NYHA functional class II-IVa  ≥3 
months prior to enrolment, despite 
optimized medical therapy 
7. Informed consent 
1. CABG or PCI ≤3 month ago or 
planned 
2. AMI ≤3 month ago 
3. Unstable angina 
4. Planned cardiac transplant 
5. Acute myocarditis 
6. Infiltrative cardiomyopathy 
7. Hypertrophic cardiomyopathy 
8. Severe primary mitral, aortic or 
tricuspid valve stenosis or 
insufficiency 
9. Tricuspid valve prosthesis 
10. Severe right ventricular dysfunction 
(RV basal diameter > 50mm) 
11. Chronic severe renal dysfunction 
(creatinine >200 µmol/l) 
12. Pregnant women or planned 
pregnancy 
13. Subjects who are unable or unwilling 
to cooperate with the study protocol 
14. Any comorbidity that is likely to 
interfere with the conduct of the study 
15. Participation in another trial 
16. Patients geographically not stable or 
unavailable for follow-up 
17. Intrinsic QRS with typical LBBB 
morphology 
AMI= Acute Myocardial Infarction; CABG= Coronary Artery Bypass Graft; ICD= 
Implantable Cardioverter Defibrillator; LBBB= Left Bundle Branch Block; LVEF= Left 
Ventricular Ejection Fraction; NYHA= New York Heart Association; PCI= Percutaneous 




4.2 Follow up and investigations 
4.2.1 Follow up         
  
4.2.1.1 Baseline and follow up visits in Part 1 
Each visits were performed by Annamaria Kosztin and Vivien Klaudia Nagy, which 
included a physical examination, assessment of the NYHA functional class, transthoracic 
echocardiography, detailed laboratory tests, 6 minute walk test and EQ5D quality of life 
measurements extended with device interrogations after the implantation. Investigations 
were performed at the baseline visit and 6 months after CRT/ICD implantation. Beyond 
regular outpatient visits, patients were contacted via telephone and the Hungarian 
National Database was used to obtain vital information at 3 years after CRT implantation 
(Figure 1) . 
 
 




4.2.1.2 Follow up in the BUDAPEST CRT upgrade study 
Eligible patients undergo a baseline evaluation including clinical history, physical 
examination, NYHA class, 12-lead ECG with paced (paced VVI or DDD 70 bpm and 
non-paced QRS complexes using VVI 40 bpm settings), transthoracic echocardiography, 
device interrogation (RV pacing percentage and Holter data), quality of life assessment 
(EQ5D), 6 minute walk test and optional NT-pro-BNP measurement. Patients are 
followed up for 12 months after randomization. Regular, in-office follow-ups will be 
performed at 1, 6 and 12 months (Table 2), which are performed by Annamaria Kosztin 
(each investigations except for echocardiography) and Attila Kovacs (echocardiography). 
While Semmelweis University is responsible for the maintenance of echocardiography 
core lab and Biobankok server, each PM interrogation files, ECGs and echocardiographic 
images that are performed during the patient follow ups from active centers, are uploaded 
to our Biobankok Server and will be analysed centrally. 
 
4.2.2 ECG  
 
By performing a 12-lead analog ECG, the assessment of QRS width and morphology 
were mandatory in each study. After all of the ECGs has been recorded, the same person 
assessed the data and fill our electronical database retrospectively.  
LBBB was defined on 12-lead ECG as QRS duration >120 ms; QS or rS in lead V1; broad 
R waves in leads I, aVL, V5, and/or V6; and absent q waves in leads V5 and V6. RBBB 
required QRS duration >120 ms; rsr, rsR, rSR, or qR in leads V1 or V2; and occasionally, 
wide R waves and wide S waves in leads I, V5, and V6. Intraventricular conduction delay 
was defined as QRS >120 ms without typical features of LBBB or RBBB.  
During BUDAPEST CRT study, the assessement of presence of intrinsic LBBB is based 
on the physicians’ discretion. The digital formation of ECGs are uploaded to the 






Echocardiography was performed according to current standards in a left lateral position 
using Philips iE33 echocardiography system equipped with an S5-1 transducer (Philips 
Healthcare, Best, The Netherlands). Image acquisition was performed according to 
current recommendations (76). Measurements were performed by the same person offline 
using the QLAB software (Philips Healthcare). Left ventricular end-systolic and end-
diastolic volumes were measured and ejection fraction was calculated by the biplane 































Inclusion criteria x     
Exclusion criteria x     
Signed Informed 
Consent 
x     
clinical history x  x x x 
physical 
examination 
x  x x x 
assessment of 
NYHA class 
x  x x x 
12-lead ECG 
(paced) 
x    x 
12-lead ECG (at 
VVI 40 bpm) 
x    x 
Echocardiography 
x    x 
device interrogation 
(print, save, upload) 
x  x x x 
blood test (NP-pro-
BNP) 
x1    x1 
6 minute walk test x2    x 
Randomization x     
Assessment of 
clinical end-points 




  x   
SAE, AE, UADE, 
USADE 
x x x x x 
Quality of life  
assessment using 
EQ-5D 
x2    x 
1: Optional, 2: After the randomization but before implantation, 3: Clinical end-points;  
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SAE= Serious Adverse Event; AE= Adverse Event; UADE= Unanticipated Adverse 
Device Effect; USADE= Unanticipated Serious Adverse Device Effect 
 
4.2.4 Serum biomarker measurements  
 
Human CT-apelin was measured by Annamaria Kosztin using C-terminus Enzyme 
Immunoassay competitive ELISA method (RayBiotech, Inc., Norcross, USA) which is 
designed to target the C-terminus of the 77-aminoacid apelin peptide. By this kit all active 
forms (apelin-13, -31, -28, and apelin-36) of the pre-prohormone 77-aa apelin peptide can 
be measured. NT-proBNP was measured with Cobas proBNP II kit (Roche Diagnostics 
Gmbh, Mannheim, Germany). Serum samples were stored at -80 oC until sample 
collection was completed. 
Rutine laboratory measurements (ions, renal function, haematology parameters) were 
performed by Eva Forizs using automatic kits (Roche kit, Roche Diagnostics Gmbh, 
Mannheim, Germany) as routine clinical practice in our hosital. 
 
4.3 Device implantation and programming 
4.3.1 Device implantation procedure in Part 1 
Device implantations were performed according to current standards by using a 
transvenous approach. By performing a coronary sinus angiogram LV lead implantation 
was tailored during device implantation. After positioning of each leads, pacing, sensing 
and impedance parameters were measured. In patients with intraoperative LV lead 
dislocation or phrenic nerve stimulation, coronary sinus stent implantation was performed 
in the CS side branch after repositioning of the LV lead (77,78). Right ventricular lead 
was primarily implanted into a septal position, while left ventricular lead into a 
posterolateral or lateral side branch. LV and RV lead positions were assessed by the 
implanting physician based on the right and left anterior oblique (RAO and LAO) views. 
 
4.3.2 Upgrade procedure in BUDAPEST CRT Upgrade study 
 
Upgrade procedures need to be performed within 14 business days after randomization. 
(Table 2). During the procedure, duration time of the upgrade, X-ray dosage, details of 
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the implanted leads, adverse events and RV-LV AD are mandantory to report. Patients 
with an existing ICD, who are randomized to the ICD arm, may not need a procedure 
unless a generator replacement, a system revision is necessary or the PI decides on 
upgrading to CRT-D in RV only pacing mode. The optional study interventions are listed 
in Table 3. Decisions about lead extraction are based on the physicians’ discretion by 
actual recommendations. (79) Use of Boston Scientific Corporation (Marlborough, MA, 
USA) ICDs or CRT-D is preferred, but not mandatory. In the ICD arm, choosing single 
or dual chamber device is left to the physician decision. In the CRT-D arm, the left 
ventricular lead is recommended to be implanted in the lateral or postero-lateral side 
branch of the coronary sinus. Transvenous implantation is strongly preferred; however, 
alternative methods are also accepted if the transvenous attempt fails. 
 
Table 3. Optional study interventions in BUDAPEST CRT upgrade study 
CRT-D group ICD group 
1. Existing PM 
Addition of RV defibrillator lead 
Addition of RA pacing lead (unless 
already has one or has permanent AF) 
Addition of LV pacing lead 
Extraction of old RV PM lead optional 
(physician’s judgment) 
Any revision of the old lead(s) and 
device pocket, as necessary 
Generator change to CRT-D 
 
2. Existing ICD 
Addition of RA pacing lead (unless 
already has one or has permanent AF) 
Addition of LV pacing lead 
Any revision of the old lead(s) and 
device pocket, as necessary 
Generator change to CRT-D 
1. Existing PM 
Addition of RV defibrillator lead 
Addition of RA pacing lead optional 
(physician’s judgment, unless already 
has one or has permanent AF) 
Extraction of old RV PM lead optional 
(physician’s judgment) 
Any revision of the old lead(s) and 
device pocket, as necessary 
Generator change to VVI or DDD ICD,  
 
1. Existing ICD 
Continue with existing device 
Addition of RA pacing lead and 
upgrading to a DDD ICD is optional 
(physician’s judgment, unless already 
has one or has permanent AF) 
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AF= Atrial Fibrillation; CRT-D= Cardiac Resynchronization Therapy with Defibrillatior; 
ICD= Implantable Cardioverter Defibrillator; PM= Pacemaker; RA= Right Atrium; RV= 
Right Ventricle 
 
4.3.3 RV-LV AD measurement at implantations 
 
After positioning both ventricular leads, intraoperative RV-LV activation delay 
measurements were performed by connecting to an electrophysiology system (Biotronik 
pacemaker interrogation device, Berlin, Germany). The right to left interventricular 
sensed delay was measured by the time delay of the peak activation in the right and left 




Figure 2.  RV-LV AD measurement by assessment of the time delay between the 





4.3.4 Device programming during BUDAPEST CRT UPGRADE study 
 
Regarding bradycardia parameters DDD(R) or VVI(R) mode is required with base rate 
setting between 40-70 bpm. In order to achieve the optimal AV-delay, SMART AV (63) 
or echocardiographic optimization or fixed values (sensed AV delay 120-140 ms/ paced 
AV delay 140-160 ms) can be used. Regarding antitachycardia parameters, two zones are 
recommended: VT1 as a monitor zone between 170-200 bpm without programmed 
therapy and VF zone over 200 bpm with a 2.5 sec delay, ATP during charging (8 pulses 
at 88% of the tachycardia cycle length) and subsequent shocks (first : DFT + 10J or 30 J, 
subsequent shocks should be maximum energy shocks). 
 
4.4 Endpoints  
4.4.1 Endpoints of Part 1. 
4.4.1.1 Endpoints in assessing the predictive value of NT-proBNP and a novel 
biomarker, CT-apelin 
The primary endpoint of the study was non-response to CRT defined as an absolute 
increase of less than 4% in ejection fraction (80) at 6 months, compared to baseline 
measurements. Secondary endpoint was all-cause mortality during the three years follow-
up. 
 
4.4.1.2 Endpoints in evaluating the effect of RV-LV AD specified by QRS 
morphology  
The primary composite endpoint was heart failure hospitalization or all-cause mortality. 
Secondary endpoint was death from any cause. 
Heart failure events were defined as symptoms and signs of heart failure that required 
intravenous diuretic treatment during an in-hospital stay. All-cause mortality was 
assessed by the National Health Fund Death Registry.  
We also evaluated the clinical outcome as changes of ejection fraction, distance walked 
during the 6-minute walk test and NT-proBNP serum levels after 6-month. 
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First the recent endpoints were assessed by RV-LV AD as a continuous variable in the 
total patient cohort, then patients were dichotomized by the lower quartile of RV-LV AD 
(86 ms)  
1) patients with RV-LV AD < 86 ms 
2) and those with RV-LV AD ≥ 86 ms 
 
 
Thereafter they were further grouped by their baseline LBBB morphology:  
 1) patients with RV-LV AD < 86 ms and LBBB 
 2) patients with RV-LV AD  ≥86 ms and LBBB 
 3) patients with RV-LV AD < 86 ms and non-LBBB 
 4) patients with RV-LV AD ≥ 86 ms and non-LBBB 
 
Finally we also investigated the outcomes of two subgroups: patients with LBBB and 
RV-LV AD < 86 ms together with patients with non-LBBB (“expected CRT non-
responders”) and compared them to patients with LBBB but RV-LV AD ≥ 86 ms 
(“expected CRT responders”).  
Our analyses were extended by RV-LV AD to QRS duration (RV-LV AD /QRS), 
moreover in order to further assess the effects of RV-LV AD as a continuous parameter 
on NT-proBNP and clinical outcome of HF/death, we evaluated the changes in NT-





4.4.2 Endpoints of Part 2. 
4.4.2.1 Endpoints in the meta-analysis of patients after CRT upgrade compared to de 
novo CRT implantation  
We report data about all-cause-mortality, heart failure events, echocardiographic (LVEF, 
EDV), clinical (change of NYHA functional class) and ECG (change of QRS width) 
parameters of reverse remodeling.  
 
 
4.4.2.2 Endpoints in the BUDAPEST-CRT upgrade study 
The primary endpoint of the study is a composite endpoint of heart failure events, all-
cause mortality, or less than 15% reduction in echocardiography determined left 
ventricular end-systolic volume from baseline to 12-month.  
Secondary end points are the composite of heart failure events and all-cause mortality, 
all-cause mortality alone, the changes of echocardiographic parameters (left ventricular 
end-diastolic volume or left ventricular ejection fraction) from baseline to 12 month.  
Tertiary endpoints are the success and safety of implantation procedures, the change of 
NYHA class, quality of life assessed by EQ-5D questionnaire,  6-minute walk test and 
the changes of NT-pro-BNP serum levels from baseline to 12 months. 
 
 
4.5 Statistics and methods for analyses  
4.5.1 Statistical analysis  
Statistical analyses were performed by Graph Pad version 6.0 and 7.0 (Graph Pad Inc., 
CA, USA), SPSS version 9 (IBM, NY, USA) or Comprehensive Meta-Analysis 3.3 
(Biostat, Inc., USA).  
Continuous variables with normal distributions are expressed as mean±SD, while those 
with non-normal distributions as medians with interquartile range (IQR). Categorical 
variables are shown with numbers and percentages (n, %). Baseline clinical 
characteristics of Part 1 were compared by unpaired t-test for normally distributed 
continuous variables, the Mann–Whitney U-Test for non-normally distributed variables, 
while 2 - test or Fisher exact test was used for dichotomous variables, as appropriate.  
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Time-to-event data were presented by Kaplan-Meier curves. Unadjusted hazard ratios 
(HR) with 95 confidence intervals (95% CI) were calculated for mortality in Cox 
proportional hazards models, while adjusted HR in forward stepwise Cox proportional 
model adjusting for relevant clinical parameters as appropriate. A two-sided p-value of 
<0.05 was considered as statistically significant.  
Univariate and multivariable receiver-operating characteristic (ROC) curve analyses were 
also used to determine the discriminatory capacity of biomarkers on non-response and 
were shown as the area under curve (AUC) and p values. In case of a significant p value, 
an optimal cutoff was assessed for the continuous variable based on maximal sensitivity 
and specificity. Using these cutoffs, patients were separated to low and high biomarker 
level groups for logistic regression analyses. Multivariate logistic regressions were 
performed with variables showing a p value less than 0.05 in univariate analyses. 
In the meta-analyses heterogeneity between individual trial estimates was assessed by the 
Q statistic and I2 statistic (81). Since, there was significant heterogeneity in the design 
and patient’s characteristics of the studies included into the meta-analyses, it was assumed 
that the true effect size varies from one study to the next, and hence the random-effect 
model was used(82). A forest plot was created with individual trials and the pooled 
estimates. Publication bias was assessed using the funnel plot, the trim and fill method of 
Duval and Tweedie (83) and an adjusted rank-correlation test according to Begg and 
Mazumdar(84). Since we did not have access to individual patient data from all studies 
reviewed, the median of delta values for LVEF, EDV, NYHA and QRS were calculated 
and compared between the two patient groups separately by using the Mann-Whitney U 
test. Methodological quality of all studies was assessed using the Methodological Index 
for Non-Randomized Studies (MINORS)(85). Studies were defined to be low, moderate 
and high quality studies based on their MINORS scores of <8, <16, and ≥16 points (data 
are not shown).  
 
4.5.2 Study selection for systematic review and meta-analyses 
 
The systematic review was performed according to the PRISMA Statement (86) and a 
predefined review protocol was published in the PROSPERO database under the 
registration number of CRD42016043747. A comprehensive search of PubMed, Research 
Gate, and Google Scholar databases was performed from January 2006 to June 2016 
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focusing on full-sized, peer-reviewed, English language papers reporting data on patient 
outcomes after upgrade CRT vs. de novo implantations as a comparator group. Abstracts 
were only included when critically relevant and not available as full-text articles. In order 
to identify all potentially relevant articles, the search was performed by using the terms 
of 1. “upgrade” AND “CRT”; 2. “upgrade” AND “cardiac resynchronisation therapy”. 
The search was also extended by using the name of the most frequently cited authors of 
the identified studies. In addition, references of relevant review articles were also 
searched to find appropriate manuscripts. Potentially relevant articles were evaluated by 
three independent reviewers and additional manuscripts were retrieved that either 
reviewer felt were potentially relevant. According to our review protocol studies were 
accepted for analysis if (i) including heart failure patients with reduced ejection fraction 
(HFrEF) with de novo and upgrade CRT implantations (ii) reporting all-cause-mortality 
data or heart failure events; (iii) reporting echocardiographic (i.e. LVEF, EDV) or clinical 
(NYHA class) or ECG (QRS width) parameters of reverse remodeling (Table 4). Heart 
failure events were defined as hospitalization due to progression of heart failure. In order 
to evaluate the heterogeneity of patients who were enrolled into each therapy groups, the 
most important baseline clinical characteristics were collected. Data on procedure related 




Table 4. Searching methodology and eligibility criteria for the meta-analysis 
Eligibility criteria 
Criteria Included Excluded 
Participants wide QRS, NYHA II – 
ambulatory IV and EF≤ 35% 
No indication for CRT 
Intervention CRT upgrade  Unsuccessful LV lead 
implantation 
Comparator de novo CRT implantation No comparator group 
Primary 
Outcome 
All-cause mortality Only cause specific mortality 




Changes in NYHA class, 
Echocardiographic parameters 
of reverse remodeling, QRS 
narrowing 
NA 
Study Design Randomized controlled trials 
Non-randomized trials 




Languages English Any other languages 
Publication 
status 
Published or accepted 




CRT= Cardiac Resynchronization Therapy; LV= Left Ventricle; NA= not applicable; 
NYHA= New York Heart Association  
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4.5.3 Sample size calculation and statistical methods in the BUDAPEST CRT 
UPGRADE study 
 
Altogether 360 patients are planned to enroll to the study. The main objective is to 
investigate the primary composite clinical and echocardiographic endpoint after CRT 
upgrade (superiority of CRT-D upgrade vs. ICD only). Analyses will be performed (i) on 
an intention-to-treat-basis (without regard to device actually implanted/revised), (ii) and 
on efficacy basis, censoring follow-up when a patient crosses over to a different device. 
The primary analyses will be stratified by the percentage of baseline RV pacing as pre-
specified in the study. The null hypothesis for the primary endpoint is that the hazard rate, 
which is assumed to be constant across all study intervals, is identical in the two groups 
(CRT-D v. ICD). The hypothesis will be tested in a study in which subjects are entered 
and followed up until (i) the primary composite endpoint occurs, (ii) the patient drops out 
of the study, (iii) or the study ends while the patient is still being followed, in which case 
the patient is censored.  
Power was calculated a priori based on a hazard ratio of 0.7 and a primary 
composite endpoint event rate of 80% in the ICD group over 12 months. The power 
calculation was based on higher RV pacing rates, while no data is available <40%.   
Although the risk seems to correlate with RV pacing, the exact correlation is unclear. The 
attrition (drop out) rate was assumed at 0.01/interval. An instantaneous hazard rate of 
0.134 for the ICD group and 0.094 for the CRT-D group was assumed – this equals to a 
median survival time of 5.17 intervals in the ICD group and 7.38 intervals in the CRT-D 
group, a cumulative event free survival at 12 intervals of 0.2 for the ICD group and 0.32 
for the CRT-D group. The two-tailed alpha was set at 0.05. A total of 144 patients will be 
entered into the ICD group and 216 into the CRT-D group to achieve a power of 80.1% 




5 RESULTS   
5.1 Part 1 – Optimization of patient selection and intraoperative techniques in 
order to achieve a more beneficial clinical response 
 
5.1.1 Optimal patient selection by measuring NT-proBNP and a novel biomarker, 
serum CT-apelin        
  
5.1.1.1 Baseline clinical characteristics 
From those patiens who underwent a successful CRT implantation between September 
2009 and December 2010, 81 patients were included in the current study. Mean age of 
the recruited patients was 64.9±10.5 years, with a mean ejection fraction of 28.5±6.5%, 
and mean QRS width of 167.7 ± 29.8 ms. Eighty-six percent of the patients had typical 
LBBB morphology and  59% had CRT-D device. Seventy-five percent of the patients 
were in NYHA class III functional state and 59 % had ischemic etiology before CRT 
implantation (Table 5a). 
 
5.1.1.2 Response and prognosis 
During the mean follow-up time of 795 ± 99 days, 7 (9%) patients died. Based on the pre-
defined classification of response, 15 (18.5%) patients proved to be non-responders,  of 
which 4 died during the follow up. Baseline clinical characteristics, medical therapy and 
echocardiographic findings were similar between responders and non-responders (Table 
5a, 5b, 5c). In line with the definition of response, left ventricular volumes significantly 
decreased (ESV: 179.1 ± 64.9 vs. 117.9 ± 58.9, p<0.0001, EDV: 248.6± 80.2 vs. 196.7 ± 
77.5, p<0.0001) and left ventricular function significantly improved (EF: 28.1 ± 6.0 vs. 
41.3 ± 7.9) in responder patients after CRT implantation, while these parameters remained 


















Age (yrs, mean±SD) 64.9 ± 10.49 64.1± 10.8 68.5 ± 8.4 0.14 
Gender (female, n, %) 15 (18.5%) 14 (21%) 1 (7%) 0.28 
Ischemic etiology (n, %) 48 (59%) 39 (59%) 9 (60%) 1.00 
NYHA II. st (n, %) 11 (14%) 9 (14%) 2 (13%) 1.00 
NYHA III. st (n, %) 61 (75%) 49 (74%) 12 (80%) 0.75 
NYHA IV. st (n, %) 9 (11%) 8 (12%) 1 (7%) 1.00 
QRS (ms, mean±SD) 167.7 ± 29.8 166.6 ± 28.8 172.0 ± 34.3 0.53 
typical LBBB 
morphology (n, %) 
70 (86%) 57 (86%) 13 (87%) 1.00 
not typical LBBB (n, %) 11 (14%) 9 (14%) 2 (13%) 1.00 




307.3 ± 127.6 329.2 ± 54.1 0.56 
RR systolic (mmHg, 
mean±SD) 
120.4 ± 18.8 121.1 ± 17.4 117.5 ± 24.8 0.51 
RR diastolic (mmHg, 
mean±SD) 
76.2 ± 10.7 76.9 ± 10.2 73.1 ± 12.3 0.21 
Heart rate (min-1, 
mean±SD) 
75.6± 14.5 75.6 ± 14.1 75.3 ± 16.5 0.93 
Atrial fibrillation (n, %) 20 (25%) 14 (21%) 6 (40%) 0.18 
Body mass index (BMI; 
med, IQR) 
27.0 (24 / 
30) 
27.0  (24 / 30) 29.0  (26 / 31) 0.16 
LBBB = left bundle branch block; NYHA class  = New York Heart Association class; 
PCI= percutaneous coronary intervention; CABG = coronary artery bypass grafting; VF= 
ventricular fibrillation  
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Table 5b. Baseline medical history, echocardiographic parameters and serum peptides 
in the responder and non-responder patients 
 
Medical history     
Hypertension (n, %) 63 (78%) 51 (77%) 12 (80%) 1.00 
Type 2 DM (n, %) 25 (31%) 22 (33%) 3 (20%) 0.37 
Prior PCI (n, %) 25 (31%) 20 (30%) 5 (33%) 1.00 
Prior  CABG (n, %) 14 (17%) 11 (17%) 3 (20%) 0.72 
Prior  stroke (n, %) 8 (10%) 6 (9%) 2 (13%) 0.64 
Prior COPD (n, %) 10 (12%) 8 (12%) 2 (13%) 1.00 
Prior dyslipidaemia (n, 
%) 
28 (35%) 20 (30%) 8 (53%) 0.13 
Prior major arrhythmia - 
VF 
(n, %) 
3 (4%) 2 (3%) 1 (7%) 0.46 
Prior ICD implantation 
(n, %) 





    
LV ejection fraction 
(Simpson%, mean±SD) 
28.5 ±6.5 28.1 ± 6.0 30.4 ± 8.2 0.23 
LV end-systolic volume 
(ml, mean±SD) 
183.5 ± 63.3 179.1 ± 64.9 203.0 ± 51.5 0.22 
LV end-diastolic  
volume 
(ml, mean±SD) 
254.7 ± 79.1 248.6± 80.2 281.5 ± 67.9 0.18 







(1173 / 4616) 
3126 
(1238 / 4492) 
0.61 












DM = diabetes mellitus; PCI= percutaneous coronary intervention; CABG = coronary 
artery bypass grafting; COPD = chronic obstructive pulmonary disease; VF= ventricular 
fibrillation 




therapy (n, %) 
    
Beta blocker (n, %) 74 (91%) 60 (91%) 14 (93%) 1.00 
ACE inhibitor or ARB 
(n, %) 
77 (95%) 63 (96%) 14 (93%) 0.57 
Spironolactone (n, %) 56 (69%) 46 (70%) 10 (67%) 1.00 
Eplerenone (n, %) 7 (9%) 5 (8%) 2 (13%) 0.61 
Furosemide (n, %) 62 (77%) 49 (74%) 13 (87%) 0.50 
Hydrochlorotiazide (n, 
%) 
9 (11%) 7 (11%) 2 (13%) 0.67 
Hydralazine (n, %) 5 (6%) 4 (6%) 1 (7%) 1.00 
Digoxin (n, %) 23 (28%) 20 (30%) 3 (20%) 0.54 
Amiodarone (n, %) 23 (28%) 19 (29%) 4 (27%) 1.00 
Statin (n, %) 50 (62%) 38 (58%) 12 (80%) 0.15 
Aspirin (n, %) 38 (47%) 34 (52%) 4 (27%) 0.10 
Clopidogrel (n, %) 20 (25%) 17 (26%) 3 (20%) 0.75 
Oral anticoagulant 
therapy (n, %) 
26 (32%) 19 (29%) 7 (47%) 0.22 





Table 6. Changes in echocardiographic parameters 6 months after CRT compared to 
baseline 
Responder patients Baseline Follow up p value 
LV ejection fraction 
(Simpson%, mean±SD) 
28.1 ± 6.0 41.3 ± 7.9 <0.0001*** 
LV end-systolic volume (ml, 
mean±SD) 
179.1 ± 64.9 117.9 ± 58.9 <0.0001*** 
LV end-diastolic  volume (ml, 
mean±SD) 
248.6± 80.2 196.7 ± 77.5 <0.0001** 
Non-responder patients    
LV ejection fraction 
(Simpson%, mean±SD) 
30.4 ± 8.2 29.3 ± 7.1 0.34 
LV end-systolic volume (ml, 
mean±SD) 
203.0 ± 51.5 194.8 ± 46.9 0.38 
LV end-diastolic  volume (ml, 
mean±SD) 
281.5 ± 67.9 271.6 ± 56.1 0.43 




According to Cox-regression analysis, non-responders had an almost four-fold higher risk 
for mortality compared with responders (HR: 3.75; 95% CI: 1.00-13.97; p=0.049) (Figure 
3). This impact on mortality persisted also in the multivariate model, with non-response 








5.1.1.3 Biomarkers to identify non-responders 
At baseline, serum CT-apelin and NT-proBNP levels were similar in both responders and 
non-responder patients (p=0.74), (Table 5) and ROC testing showed that these parameters 
are not predictors of non-response (apelin: AUC 0.48; 95%CI: 0-29-0.70; p=0.87, NT-
proBNP: AUC 0.53; 95%CI: 0-37-0.70; p=0.73). 
At six months, serum CT-apelin significantly decreased in responders (from 549.5 ng/ml 
[IQR: 279.0-868.8] to 211.0 ng/ml [IQR: 113.8-416.8]; p<0.0001), while it remained 
unchanged in non-responder patients (from 472.5 ng/ml [IQR: 307.8-700.3] to 541.0 





Table 7. Changes in serum peptide levels between responder and. non-responder patients 
after CRT implantation 
Responder patients Baseline Follow up p value 
CT-apelin (ng/ml, med, 
IQR) 




med, IQR)  







   
CT-apelin (ng/ml, med, 
IQR) 
472.5 (307.8 / 700.3) 541.0 
(278.3/831.0) 
0.80 
NT-proBNP (pg/ml,  
med, IQR)  










Similarly, NT-proBNP levels significantly decreased in responders at 6 months (median: 
2561 pg/ml, IQR: 1173-4616 to 1253 pg/ml IQR: 516-2519; p=0.007), while it remained 
unchanged in non-responder patients (median: 3126 pg/ml [IQR: 1238-4492] to 2676 





Figure 4. Changes in CT-apelin and  NT-proBNP levels according to response to CRT 
 
In ROC analysis, both 6-month CT-apelin and NT-proBNP levels significantly 
discriminated between responder and non-responder patients (CT-apelin: AUC 0.78; 
95%CI: 0.59-0.97; p<0.01, NT-proBNP: AUC 0.75; 95%CI: 0.62-0.88; p=0.005). 
According to the highest sensitivity and specificity, the optimal cutoffs to diagnose non-
response were 268.5 ng/ml for CT-apelin and 1348.5 pg/ml for NT-proBNP, respectively.  
When patients were classified into groups according to optimal cutoff values, patients 
with high serum CT-apelin showed a 10 times higher odds for non-response (OR: 10.3, 
95% CI;  1.16-91.43; p=0.04), while higher NT-proBNP levels indicated a 16-fold odds 
for non-response in our patient cohort (OR: 16.0, 95% CI; 1.96-130.68 ;  p=0.01). 
However, Multivariate ROC testing suggested the superiority of CT-apelin over NT-
proBNP (CT-apelin: AUC 0.78; 95%CI: 0-59-0.97; p=0.013 vs. NT-proBNP: AUC 0.67; 
95%CI: 0.49-0.85; p=0.13, Figure 5) that was also confirmed in multivariate logistic 





Figure 5. Receiver–Operator Characteristic Curve analysis comparing the diagnostic 
performance of 6-month serum CT-apelin and NT-proBNP levels on identifying non-




5.1.2 The role of an intraoperative parameter, the RV-LV AD measuring during CRT 
implantation 
 
5.1.2.1 Baseline clinical characteristics 
Between September 2009 and December 2010, 125 patients were enrolled in this study, 
73 patients (58%) received CRT-D, while 52 patients (42%) were implanted with a CRT 
with pacemaker (CRT-P). The mean age of the study participants was 67.0 ± 8.6 years, 
the mean EF was 28.2 ± 6.5%. Majority of the patients (71%) were in NYHA functional 
class III, 62% of them had LBBB and 60% had ischemic cardiomyopathy. The RV-LV 
AD measurements were ranged between 40 and 175ms, the mean value was 106.10 ± 
29.98 ms in the entire patient cohort, 109.80 ± 30.31 ms in the LBBB group, 100.0 ± 
28.72 ms in the non-LBBB group  (p=0.07).  
Baseline clinical characteristics of patients with an RV-LV AD below or equal and above 
86 ms (lower quartile) are listed in Table 8a and Table 8b. Notably, there were no major 
differences among patients with a shorter or longer RV-LV AD in clinical or 
echocardiographic parameters.  
After we further dichotomized the patient cohort by LBBB morphology, we assessed the 
baseline clinical characteristics in patients with LBBB and RV-LV AD  ≥  86 ms and 
compared to the group of remaining patients such as LBBB and RV-LV AD < 86 ms and 
patients with non-LBBB together. In the group of LBBB and RV-LV AD  ≥  86 ms, lower 
percent of the patient population had ischemic etiology (50% vs. 69%; p=0.04) or prior 
CABG (12% vs. 26%; p=0.04), had higher mean LV ESV (194.5±70.0ml vs. 168.3±56.4 
ml; p= 0.04), less patients were in ambulatory NYHA IV functional class (8% vs. 3%; p= 
0.01), and more had sinus rhythm (82% vs. 51%; p= 0.001) at enrolment compared to the 
group of LBBB and RV-LV AD < 86 ms and patients with non-LBBB together (Table 8c 




Table 8a. Baseline clinical characteristics of CRT patients by RV-LV AD of 86 ms at 
device implantation 
 
RV-LV AD ≥ 
86ms (n=95) 




Age in years (mean±SD) 67.1±8.3 66.5±9.7 0.73 
Female gender (n, %) 18 (19%) 6 (20%) 1.00 
CRT-D (n, %) 53 (56%) 20 (67%) 0.39 
RV-LV AD (ms; mean±SD) 117±23 69±13 NA 
Baseline medical history    
Ischemic etiology (n, %) 56 (60%) 19 (63%) 0.25 
Diabetes mellitus (n, %) 31 (32%) 6 (20%) 0.25 
Secondary prevention (n, %) 5 (4%) 5 (17%) 0.06 
Prior myocardial infarction (n, %) 31 (32%) 14 (47%) 0.19 
CABG (n, %) 17 (18%) 7 (23%) 0.60 
Baseline clinical assessment    
Sinus rhythm at enrolment (n, %) 64 (67%) 18 (60%) 0.51 
QRS at baseline (ms, mean±SD) 166.4±27.7 170.0±33.9 0.57 
LBBB ECG morphology (n, %) 60 (63%) 18 (60%) 0.23 
RBBB ECG morphology (n, %) 0 (0%) 2 (7%) 0.06 
IVCD ECG morphology (n, %) 35 (37%) 10 (33%) 0.83 
NYHA II (n, %) 16 (17%) 2 (6%) 0.24 
NYHA III (n, %) 69 (73%) 23 (77%) 0.81 
NYHA IVa (n, %) 10 (10%)  5 (17%) 0.35 
6-minute walk test (m, mean±SD) 307.4±128.8 268.1±128.6 0.22 
Systolic blood pressure (mmHg, 
mean±SD) 
119.9±17.5 122.5±20.8 0.52 
Heart rate at baseline (bpm, 
mean±SD) 
75.8±46.4 73.7±11.3 0.59 
RV-LV AD= Right to left ventricular activation delay; CABG= coronary artery bypass 
graft; LBBB= left bundle branch block; RBBB= right bundle branch block; IVCD= 
intraventricular conduction delay   
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Table 8b. Baseline medical therapy, laborator and echocardiographic parameters of 
CRT patients by RV-LV AD of 86 ms at device implantation 
Baseline medical therapy     
Beta blocker (n, %) 86 (91%) 24 (83%) 0.19 
ACE inhibitor or ARB (n, %) 91 (96%) 27 (93%) 0.36 
Spironolactone (n, %) 69 (74%) 18 (62%) 0.25 
Loop diuretics (n, %) 77 (82%) 23 (80%) 0.61 
Laboratory parameters    
NT-proBNP (ng/ml; med, IQR) 
2608.0 
(1596/4945) 
2815.0 (1232/4732) 0.88 
Creatinine (umol/L; med, IQR) 106.8 ±34.8 118.0 ±41.6 0.20 
BUN (mmol/L; mean±SD) 9.2 ± 1.4 10.7 ± 7.0 0.18 
Echocardiography parameters    
LVEF (%, mean±SD) 28.5±5.5 28.1±6.9 0.82 
LV end-diastolic volume (ml, 
mean±SD) 
249.6±49.3 253.4±82.7 0.86 
LV end-systolic volume (ml, 
mean±SD) 
181.4±50.4 184.0±67.4 0.85 
ACE= angiotensin converting enzyme inhibitor; ARB= angiotensin receptor blocker; 





Table 8c. Baseline clinical characteristics of CRT patients by RV-LV AD of 86 ms and 
LBBB morphology  
 
RV-LV AD ≥ 86ms  
LBBB patients 
(n=60) 
RV-LV AD < 86 ms  
LBBB and nonLBBB 
patients (n=65) 
p-value 
Age in years (mean±SD) 67.5±7.9 66.3±9.6 0.49 
Female gender (n, %) 16 (27%) 8 (12%) 0.07 
CRT-D (n, %) 32 (53%) 41 (63%) 0.28 
RV-LV AD (ms; mean±SD) 121±23 92±28 NA 
Baseline medical history    
Ischemic etiology (n, %) 30 (50%) 45 (69%) 0.04* 
Diabetes mellitus (n, %) 16 (27%) 21 (32%) 0.23 
Secondary prevention (n, %) 2 (3%) 8 (12%) 0.10 
Prior myocardial infarction (n, %) 17 (28%) 28 (43%) 0.10 
CABG (n, %) 7 (12%) 17 (26%) 
0.04* 
Baseline clinical assessment    
Sinus rhythm at enrolment (n, %) 49 (82%) 33 (51%) 0.001*** 
QRS at baseline (ms, mean±SD) 167.3±24.5 167.2±33.3 0.98 
LBBB ECG morphology (n, %) N/A 18 (28%) N/A 
RBBB ECG morphology (n, %) N/A 2 (3%) N/A 
IVCD ECG morphology (n, %) N/A 45 (69%) N/A 
NYHA II (n, %) 9 (15%) 6 (9%) 0.41 
NYHA III (n, %) 46 (77%) 44 (68%) 0.32 
NYHA IVa (n, %) 5 (8%)  15 (23%) 
0.01* 
6-minute walk test (m, mean±SD) 316.0±132.6 282.9±125.2 0.22 
Systolic blood pressure (mmHg, 
mean±SD) 
119.8±18.9 121.1±17.8 0.70 
Heart rate at baseline (bpm, 
mean±SD) 
76.8±13.8 77.0±20.8 0.97 
RV-LV AD= Right to left ventricular activation delay; CABG= coronary artery bypass 
graft; LBBB= left bundle branch block; RBBB= right bundle branch block; IVCD= 
intraventricular conduction delay   
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Table 8d. Baseline medical therapy, laboratory and echocardiographic parameters of 
CRT patients by RV-LV AD of 86 ms and LBBB morphology  
 
Baseline medical therapy     
Beta blocker (n, %) 54 (90%) 56 (88%) 0.59 
ACE inhibitor or ARB (n, %) 58 (97%) 60 (94%) 0.44 
Spironolactone (n, %) 42 (70%) 45 (70%) 1.00 
Loop diuretics (n, %) 45 (75%) 55 (86%) 0.19 
Laboratory parameters    
NT-proBNP (ng/ml; med, IQR) 2608 (1063/4664) 2612.0 (1739/5049) 0.21 
Creatinine (umol/L; med, IQR) 101.9 ±45.0 116.1 ±36.8 0.06 
BUN (mmol/L; mean±SD) 9.0 ± 4.7 10.1 ± 5.4 0.21 
Echocardiography parameters    
LVEF (%, mean±SD) 27.6±7.6 28.0±6.6 0.77 
LV end-diastolic volume (ml, 
mean±SD) 
263.1±86.1 233.5±69.1 0.08 




ACE= angiotensin converting enzyme inhibitor; ARB= angiotensin receptor blocker; LV= left 
ventricular; LVEF= left ventricular ejection fraction; BUN= blood urea nitrogen. 




5.1.2.2 RV-LV activation delay and functional outcome 6 months after CRT 
implantation 
At 6-month follow up, 33 (55%) of the patients with RV-LV AD ≥ 86 ms and LBBB 
performed their 6-minute walk test over 300 meters, compared to 23 of those patients 
(35%) with RV-LV AD < 86 ms or with a non-LBBB (55% vs. 35%; p=0.03) (Table 9). 
In patients with RV-LV AD ≥ 86 ms and LBBB, better laboratory parameters were 
observed at 6-month after CRT implantation with an NT-proBNP median value of 1216 
(IQR: 326.9 / 2630) vs. 1887 (IQR: 1140 / 3300); p = 0.03, a creatinine value of 96.3 ± 
56.6 vs. 122.1 ± 46.9; p = 0.01 and a blood urea nitrogen value of 7.6 ± 4.7 vs. 10.9 ± 5.6; 
p = 0.001, as compared to non-LBBB patients or to those with LBBB and RV-LV AD < 
86 ms (Table 9). Patients with RV-LV AD ≥ 86 ms and LBBB showed the greatest 
improvement in left ventricular ejection fraction (EF: 28.0 ± 7.1 to 36.3 ± 12.3; p < 0.001) 
6-month after CRT implantation. 
 
5.1.2.3 RV-LV activation delay and clinical outcome in the total patient cohort 
During the median follow-up of 2.2 years, 44 (35%) patients had heart failure events or 
death, out of them 36 (29%) patients died. Sixteen (53%) patients had HF or death with 
RV-LV AD < 86 ms, and 28 (29%) with RV-LV AD ≥ 86 ms, while 11 (37%) patients 
died with RV-LV AD < 86 ms, and 25 patients (26%) with RV-LV AD ≥ 86 ms. 
Patients with RV-LV AD ≥ 86 ms had significantly lower cumulative probability 
of HF/death when compared to those with RV-LV AD < 86 ms (p=0.003) (Figure 6a). 
The cumulative probability of all-cause mortality was significantly lower in patients with 
a longer activation delay (RV-LV AD ≥ 86ms) compared to those with shorter delay (RV-






Table 9. Clinical parameters at 6-month after CRT implantation 
Clinical assessment 










6-minutes walk test > 300 m 
(n; %) 
33 (55%) 23 (35%) 0.03* 
Systolic blood pressure  
(Hgmm, mean±SD) 
127.4 ± 19.3 122.2 ± 24.8 0.27 
Diastolic blood pressure 
(Hgmm, mean±SD) 
77.2 ± 9.4 73.2 ± 12.0 0.08 
Laboratory parameters    
NT-proBNP  
(ng/ml; med, IQR) 
1216 (326.9 / 2630) 1887 (1140 / 3300) 0.03* 
Creatinine  
(umol/L; med, IQR) 
96.3 ± 56.6 122.1 ± 46.9 0.01* 
Blood Urea Nitrogen 
(mmol/L; mean±SD) 
7.6 ± 4.7 10.9 ± 5.4 0.001** 














Multivariate Cox-regression analysis confirmed the independent role of RV-LV AD first 
as a continuous parameter (Table 10a) and then by 86 ms  (Table10b) in predicting HF or 
death or all-cause mortality in the total patient population after adjustment for relevant 
clinical covariates, namely for LBBB ECG morphology, heart failure etiology and age at 
enrolment. Patients with RV-LV AD ≥ 86ms had a 56% significantly lower risk of HF or 
death (HR: 0.44; 95% CI: 0.23-0.82; p=0.001) and a 52% lower risk of all-cause mortality 
(HR: 0.48; 95% CI: 0.23-1.00; p=0.05), compared to those with a shorter RV-LV 
activation delay at CRT implantation (Table 10b). 
 
Table 10a. Univariate models to evaluate the clinical outcome of CRT patients by 
continuous value of RV-LV AD and LBBB ECG morphology at baseline 
Primary end point: 







RV-LV AD in all patients 
(125 patients) 
0.98 0.97 – 0.99 0.015* 
RV-LV AD in LBBB 
(78 patients) 
0.98 0.96-0.99 0.029* 
RV-LV AD in non-LBBB 
(47 patients) 
0.99 0.97 – 1.00 0.36 








RV-LV AD in all patients 
(125 patients) 
0.98 0.97-0.99 0.0001*** 
RV-LV AD in LBBB 
(78 patients) 
0.97 0.96-0.99 0.03 
RV-LV AD in non-LBBB 
(47 patients) 
0.12 0.97 – 1.00 0.98 
LBBB= Left Bundle Branch Block; LV= Left Ventricle; RV= Right Ventricle; RV-LV 




Table 10b. Multivariate models of primary endpoint to evaluate the clinical outcome of 
CRT patients by RV-LV AD and LBBB ECG morphology at baseline 
Primary end point: 







RV-LV AD ≥86ms vs. <86ms in all 
patients 
(95 vs. 30 patients) 
0.44 0.23 – 0.82 0.001* 
RV-LV AD ≥86ms vs. <86ms in LBBB 
(60 vs. 18 patients) 0.18 0.63-0.52 0.001* 
RV-LV AD ≥86ms vs. <86ms in non-
LBBB 
(35 vs. 12 patients) 
0.63 0.26 – 1.49 0.29 
RV-LV AD ≥86ms in LBBB vs. Others 
(60 vs. 65 patients) 0.23 0.11 – 0.49 <0.001* 
LBBB= Left Bundle Branch Block; LV= Left Ventricle; RV= Right Ventricle; RV-LV 
AD= Right to Left Ventricular Activation Delay 
*Models are adjusted for age at enrolment, ischemic etiology of heart failure, and for 
LBBB ECG pattern in the model on the total patient population.  
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Table 10c. Multivariate models of secondary endpoint to evaluate the clinical outcome 
of CRT patients by RV-LV AD and LBBB ECG morphology at baseline 








RV-LV AD ≥86ms vs. <86ms in all 
patients 
(95 vs. 30 patients) 
0.48 0.23-1.00 0.05* 
RV-LV AD ≥86ms vs. <86ms in LBBB 
(60 vs. 18 patients) 
0.37 0.12-1.18 0.09 
RV-LV AD ≥86ms vs. <86ms in non-
LBBB 
(35 vs. 12 patients) 
0.43 0.15 – 1.20 0.11 
RV-LV AD ≥86ms in LBBB vs. Others 
(60 vs. 65 patients) 
0.35 0.16 – 0.75 0.007* 
LBBB= Left Bundle Branch Block; LV= Left Ventricle; RV= Right Ventricle; RV-LV 
AD= Right to Left Ventricular Activation Delay 
*Models are adjusted for age at enrolment, ischemic etiology of heart failure, and for 





5.1.2.4 RV-LV activation delay and clinical outcome by LBBB ECG pattern 
The findings were even more pronounced in patients with an LBBB ECG pattern. Patients 
with an LBBB and an RV-LV AD ≥ 86 ms at implantation had a significantly lower 
cumulative probability of HF/death when compared to those with shorter activation delay 
(RV-LV AD < 86 ms) and to those patients with non-LBBB (p<0.001) (Figure 7a). This 
difference was translated into a 77% reduction in the risk of HF or death (HR: 0.23; 95% 
CI: 0.11-0.49; p < 0.001), after adjustment for relevant clinical covariates (Table 10b). 
Furthermore, there was a significantly lower cumulative probability of all-cause mortality 
in LBBB patients with a longer RV-LV activation delay at implantation (RV-LV AD ≥ 
86ms), compared to those with shorter activation delay (RV-LV AD <86ms) and to those 
patients with non-LBBB (p=0.01) (Figure 7b). This translated into a 65% risk reduction 
in all-cause mortality in the multivariate models (HR: 0.35; 95% CI: 0.16-0.75; p=0.007) 
(Table10c).   
In patients with non-LBBB, there was no significant difference in HF or death or in all-
cause mortality by RV-LV AD groups measured at CRT implantation (HF/death 
HR=0.63; 95% CI: 0.26-1.49; p=0.29, death HR=0.43; 95% CI: 0.15-1.20; p=0.11) 





Figure 7a. Kaplan-Meier Cumulative probability of HF/Death by LBBB ECG 





Figure 7b. Kaplan-Meier Cumulative probability of Death by LBBB ECG morphology 




5.1.2.5 Clinical outcome by RV-LV activation delay after normalization to QRS 
The univariate model showed that RV-LV AD /QRS is also an independent factor of the 
primary endpoint of heart failure and death in LBBB patients (HR: 0.08; 95% CI 0.01-
1.02; p=0.05). These results were also confirmed by multivariate Cox regressional 
analysis: by using the optimal cutoff value of percentage RV-LV AD /QRS which was 
64%. Those who had higher RV-LV AD to QRS ≥ 64% have lower risk for heart failure 
events or death in the total patient cohort (HR: 0.43; 95% CI 0.23-0.81; p=0.01) and in 
LBBB patients as well (HR: 0.28; 95% CI 0.10-0.80; p=0.01). The lowest cumulative 
probability of HF/death was observed in patients with higher percentage of RV-LV AD 
/QRS and LBBB morphology (HR: 0.21; 95% CI 0.08-0.54; p=0.001) compared to 
nonLBBB or low RV-LV AD /QRS patients. In multivariate analyses models were 
adjusted for age and ischemic etiology. (Data are not shown). 
 
5.1.2.6 Functional outcome, NT-proBNP 6-month after CRT implantation and clinical 
outcome by RV-LV activation delay quartiles 
When we assessed the effects of RV-LV AD on changes of NT-proBNP and incidence of 
HF/death by RV-LV quartiles, we found a linear increase in the degree of reduction in 
NT-proBNP 6-month after CRT towards the longer RV-LV AD quartile sub-groups. In 
parallel with the improvement in NT-proBNP, there was a linear decrease in the incidence 
of HF/death (Figure 8). 
Besides the beneficial changes in NT-proBNP, the better clinical outcome was reflected 
in the improvement of renal function between patients with longer RV-LV AD and LBBB 
morphology compared to those, who had shorter activation delay or nonLBBB 
morphology (Table 9). Significant differences were found in changes of serum creatinine 
levels after 6 months (96.3±56.6 umol/L vs. 122.1±46.9 umol/L; p=0.01), and more 





Figure 8. Incidence of patients per HF/death events and relative changes of NT-proBNP 






5.2 Part 2 - The question of CRT upgrade  
5.2.1 A systematic review and meta-analyses from the literature about the outcome of 
patients after CRT upgrade vs. de novo CRT implantation 
 
5.2.1.1 Study characteristics 
A total of 17 reports were selected for the current analysis comprising 6628 CRT 
recipients, of whom 4549 patients had de novo resynchronization therapy and 2079 





Figure 9. Flow chart of searching for publications to the meta-analyses of CRT upgrade 
vs. de novo CRT implantation 
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The characteristics of all included studies are shown in Table 11a. None of the identified 
studies was a randomized, controlled trial. Most of them were observational, retrospective 
(87-98)(99) or observational prospective (100-102)(103) cohort studies. The vast majority 
were single-center observations (89,91-93,95-98,100,101) with the exception of four 
dual/multicenter studies(88,90,94)(88) and one based on a European survey(87). 
Four(98,100,102)(88) from the 17 studies proved to be high quality reports with an 
average MINORS score 13.9  (data are not shown).  
The most important published patient characteristics of the included studies, such as age, 
gender, etiology, baseline QRS duration (paced in upgrade and intrinsic in de novo 
group), baseline NYHA functional class, baseline left ventricular ejection fraction and 
dimensions are summarized in Table 11b. In summary, the mean ejection fraction was by 
definition lower than 35% in all studies and there were no significant differences between 
the de novo and upgrade groups in most of the individual studies. Most of the trials 
enrolled patients with severe symptoms (NYHA III-IVa), a smaller extent of the studies 
investigated patients without depicting functional class. More than 50% of the studies 
found significant differences in the following baseline parameters between the two patient 
groups: age, atrial fibrillation and QRS duration. In the upgrade group, patients were 
generally older, more likely to have atrial fibrillation and they had wider (paced) QRS.  
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Type of devices 
before upgrade 
% of ventricular 



















(VVI / VDD / DDD) 
PM dependent patients 
with constant RVAP for 
4.7 ± 2.5 years 
 
moderate 











PMs (further details are 
NA) 
>50% moderate 





79 61 18 6 months 
All-cause mortality 
(procedural parameters, 
NYHA / LVEF / NT-
proBNP) 






328 221 107 






(QoL, peak Vo2, 
dyssynchrony 
parameters) 
81% DDD  
19% VVI 
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% of ventricular 














394 336 58 






(CV death or HF 
hospitalization, 
6 MTW, QoL) 






505 338 167 









<40% in 25% of pts 
40-80% in 21% of pts 
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no further details 
>50% for at least 6 
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82 43 39 
1.3,  and every 
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thereafter 
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2090 1489 601 12 months 
All-cause mortality 




  69.9% ICD 
62% paced rhythm at 
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before upgrade 
















655 465 190 12 months 
All-cause mortality 








> 40%  moderate 





135 85 50 6 / 48 months 
All-cause mortality 
ΔEF 
(MR, Global long. 
strain) 
PMs >40%  high 




observational cohort  
268 134 134 12 months All-cause mortality 
(procedural parameters) 
PMs and ICDs; 60% 






observational cohort  
























EDV= end-diastolic volume; EF= left ventricular ejection fraction; ICD= implantable cardiac defibrillator; PM= pacemaker; DDD-
PM/ICD= dual chamber pacemaker or ICD; VVI-PM/ICD= single chamber ventricular pacemaker or ICD; Pts= patients; NYHA= New 
York Heart Association Class; MR= mitral regurgitation; RVAP= right ventricular apical pacing 
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before upgrade 
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observational cohort  
281 165 116 10 months 
All-cause mortality 





49% DDD PM, 22% 
DDD-ICD, 18% VVI, 
12% VVI-ICD 
<40% in 13% of pts 
40-80% in 16% of pts 

















Table 11b. Differences in the baseline patient characteristics of the included studies to the meta-analyses of CRT upgrade vs. de novo CRT 
implantation 
 (Parameters with significant difference in the original reports are highlighted with bold verbatim) 
 
 Gender (male) Etiology (ischemic) Atrial Fibrillation Age (years) QRS (ms) NYHA EF (%) 
LV dimensions 

















































3.2 ± .5 22 ± 5 23 ± 9 
67 ± 10 
mm 
















20 ± 1 20 ± 2 
70 ± 2 
mm 


















22 ± 7 25 ± 9 NA NA 
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Table 11b. Differences in the baseline patient characteristics of the included studies to the meta-analyses of CRT upgrade vs. de novo CRT 
implantation (continuation) 
 
 Gender (male) Etiology (ischemic) Atrial Fibrillation Age (years) QRS (ms) NYHA EF (%) 
LV dimensions 

















































63 ± 9 
mm 

























































































































                 
DOI:10.14753/SE.2017.2351
 69 
Table 11b. Differences in the baseline patient characteristics of the included studies to the meta-analyses of CRT upgrade vs. de novo CRT 
implantation (continuation) 
 
 Gender (male) Etiology (ischemic) Atrial Fibrillation Age (years) QRS (ms) NYHA EF (%) 
LV dimensions 





































23 (59%) 10 (23%) 
16 
(41%) 











































NA NA 32 ± 12 30 ± 10 NA NA 
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Table 11b. Differences in the baseline patient characteristics of the included studies to the meta-analyses of CRT upgrade vs. de novo CRT 
implantation (continuation) 
 Gender (male) Etiology (ischemic) Atrial Fibrillation Age (years) QRS (ms) NYHA EF (%) 
LV dimensions 
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Table 11b. Differences in the baseline patient characteristics of the included studies to the meta-analyses of CRT upgrade vs. de novo CRT 
implantation (continuation) 
 Gender (male) Etiology (ischemic) Atrial Fibrillation Age (years) QRS (ms) NYHA EF (%) 
LV dimensions 





































39 (80%) 44 (52%) 
29 
(58%) 
NA NA 64 ± 12 69 ± 12 
174 ± 
17 


























































23 ± 7 24 ± 7 NA NA 
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Table 11b. Differences in the baseline patient characteristics of the included studies to the meta-analyses of CRT upgrade vs. de novo CRT 
implantation (continuation) 
 Gender (male) Etiology (ischemic) Atrial Fibrillation Age (years) QRS (ms) NYHA EF (%) 
LV dimensions 




























































21 (18%) 94 (57%) 
66 
(57%) 

































































5.2.1.2 All-cause mortality and heart failure events 
Crude mortality rates were available in 6157 patients from 12 studies (87-
89,91,93,94,96,98,100,102)(84, 88), while unadjusted or adjusted hazard ratios were 
available for 1734 and 1229 patients in three (91,102) (88) and four (91,98,102)(88) 
studies, respectively. All-cause mortality did not differ following an upgrade to CRT 
compared to de novo implantations (RR 1.10, 95% CI, 0.99 to 1.22, p=0.08, 
I2=36.5%)(Figure 10a). Pooled analyses of the unadjusted or adjusted hazard ratios 
revealed similar findings (crude HR 1.07, 95% CI, 0.72 to 1.57, p=0.74, I2=73.6%)(Figure 
10b)(adjusted HR: 0.81, 95% CI, 0.36 to 1.81, p=0.61)(Figure 10c). In studies that 
provided relevant information, the unadjusted risk of heart failure events was 
significantly higher in patients with de novo implantations (RR 1.15, 95% CI, 1.04 to 
1.27, p=0.01, I2=46.5%)(Figure 10d).  
 
5.2.1.3 Left ventricular reverse remodeling, clinical improvement  
The extent of reverse remodeling in terms of improvement in left ventricular ejection 
fraction and end-diastolic volume was similar in the two patient groups (ΔEF de novo. 
6.85% vs. upgrade 9.35%, p=0.235)(Figure 11a);  (ΔEDV de novo -23.0 ml vs. upgrade 
-20.0 ml; p=0.730)(Figure 11b). Regarding symptoms, change in NYHA functional class 
was also comparable after de novo CRT implantation and upgrade procedures (ΔNYHA 
de novo - 0.74 vs. upgrade - 0.70 class; p=0.737)(Figure 11c). When QRS narrowing was 
compared, no significant difference was found between the two patient groups (ΔQRS de 




























































5.2.1.4 System-related complications 
Based on three studies (87,96,100) of 2714 patients, where detailed analyses regarding 
system-related complications were published, only fluoroscopic time(87) and the rate of 
phrenic nerve(96) stimulation showed significant difference between the two patient 
groups, favoring upgrade implantations (Table 12). 
 
Table 12. Complications during de novo CRT vs. upgrade CRT implantations 
(Parameters with significant difference in the original reports are highlithed with bold 
verbatim) 
 



















140) na na 




18 15 (8-27) 18 (11-29) na na 




31 na na na na 
Tamponade 0 0 3 4 0 2 
Perforation 0 0 na na na na 
Vena cava superior dissection 1 0 na na 0 1 
Coronary Sinus Dissection 1 1 6 25 4 4 
Pocket hematoma 0 1 26 46 na na 
Bleeding / Trasfusion due to 
bleeding 0 1 4 15 2 0 
Allergic reaction 0 1 na na na na 
PTX 0 1 3 16 1 4 
Infection 0 0 na na na na 
Lead revision / dislocation 0 2 11 48 2 5 
Phrenicus nerve stimulation na na 11 35 4 10 





5.2.2 Current status and preliminary results of the BUDAPEST CRT upgrade study 
 
5.2.2.1 Enrolment and baseline clinical characteristics 
Altogether 26 centers are participating in the study, 20 European (from Hungary, Czech 
Republic, Germany Poland, Russia, Serbia and Slovenia) and 6 Isreali sites. List of the 
European sites are shown in Table 13, from Isreali sites, only one center is active, therefor 
not included in the table. 
From November 2014 one hundred and eleven patients were included and randomized 
(Figure 12), 67 (60%) to CRT-D and 44 (40%) to ICD arm.  
In the Semmelweis University, Heart and Vascular Center 64 (58%) patients were 
enrolled. From these patients three became ineligible due to late inconsent to the study. 
From the remaining 61 patients, 36 (59%) were on CRT-D arm and 25 (41%) on ICD 
arm. From the latter group, four patients were also implanted an entire CRT-D system 
and programmed to RV only mode.  
Regarding the baseline clinical characteristics of patients in the Semmelweis University, 
the preliminary results are shown in Table 14. In our total patient cohort, 48 had 
conventional pacemaker devices and 14 had ICDs. The mean ejection fraction was 28.6 
± 4.5%, 7 (12%) patients were female, the mean age was 72.0 ± 6.1 years in the total 
patients cohort, while these parameters did not show significant differences in CRT-D 
and ICD groups (Table 14). Data are not shown about further clinical parameters, which 
are under analyses yet. 
 
5.2.2.2 Success rate and safety of upgrade procedures 
On the CRT-D arm in two cases (6%) the first attempt of LV lead implantation was not 
successful due to gracile coronary sinus branch, thereafter one patient received a 
transseptal LV lead, the other procedure is awaiting for the second attempt.  
During the procedures, in 7 (12%) cases prior implanted RV leads were extracted 








5.2.2.3 Follow up, heart failure events and all-cause mortality 
During the 28 months from the time of our first enrolment, three (5%)  patients were lost. 
Fourty-four (72%) patients completed the 12-months follow up.  
One patient on ICD arm had heart failure event, however we switched to biventricular 
pacing, he died in a non-cardiovascular event. Except for this case no other death could 
be observed yet.  
Altogether 7 heart failure events occured, each patients were on ICD arm. After the 
consideration of requiring intravenous diuretic administration with hospital admission 
and complete clinical evaluations, these patients became cross-overs and LV leads were 
switched on. Out of these patients four had no prior LV leads,  thus an upgrade had to be 
performed. This preliminary event rate was significantly higher in patients with an ICD 








Table 13. European sites of BUDAPEST CRT upgrade study 
Site 
number 
Name of Principal 
Investigators 




HU-01 Prof. Merkely 18/11/14 active 
HU-02 Dr. Duray 11/05/15 active 
HU-03 Prof. Édes 04/05/15 active 
HU-04 Dr. Sághy 18/04/16 active 
HU-05 Dr. Kónyi 05/04/16 active 
HU-06 Dr. Földesi 22/09/16  
RU-01 Prof. Pokushalov 19/07/16  
RU-02 Prof. Popov 13/07/16  
SL-01 Prof. Zupan 03/08/15  
DE-01 Prof. Hindricks 25/11/15  
DE-02 Dr. Veltmann 18/08/16 active 
DE-03 Prof. Kuck 19/10/16  
PL-01 Prof. Wranicz 18/08/15 active 
PL-02 Prof. Grabowski 01/04/16  
PL-03 Prof. Lubinski 30/03/16  
PL-04 Dr. Goscinska-Bis 29/03/16 active 
PL-05 Dr. Oreziak 13/02/17  
PL-06 Prof. Kasprzak 14/02/17  
CZ-01 Prof. Kautzner 20/10/16  







Table 14. Baseline clinical variables of patients included in the Semmelweis University 
in the BUDAPEST CRT upgrade study 











Age (yrs, mean±SD) 72.0 ± 6.1 71.5 ± 6.4 72.6 ± 5.6 0.50 
Gender (female, n, %) 7 (12%) 6 (17%) 1 (4%) 0.22 
LV Ejection fraction (%, 
mean±SD) 
28.6 ± 4.5 29.0 ± 4.0 28.0 ± 5.0 0.42 
DDD-PM 32 (52%) 20 (56%) 12 (48%) 0.61 
VVI-PM 12 (20%) 8 (22%) 4 (16%) 0.75 
VDD-PM 4 (7%) 2 (6%) 2 (8%) 1.00 
VVI-ICD 9 (15%) 4 (11%) 5 (20%) 0.47 
DDD-ICD 4 (7%) 2 (6%) 2 (8%) 1.00 
Primary Endpoints     
All-cause mortality (n, %) 0 (0%) 0 (0%) 1 (4%) 0.41 
Heart Failure Events (n, %) 7 (12%) 0 (0%) 7 (28%) 0.001 
Completed 12-months follow 
up 44 (72%) 30 (83%) 14 (56%) 0.02 
CRT-D= Cardiac Resynchronization Therapy with Defibrillator; ICD= Implantable 
Cardioverter Defibrillator; LV=Left Ventricular; PM= pacemaker - DDD-PM/ICD= 




















6.1 Optimization of patient selection and intraoperative techniques in order to 
achieve a beneficial clinical response after CRT implantation 
 
There are conclusive data in the literature about the success of de novo CRT implantations, 
which improves exercise capacity, reduces the risk of heart failure events and improves 
event-free survival (13-15). However, approximately 20-40% of patients fail to develop 
reverse remodeling and prove to be non-responders (104).  
While in average 2 to 5-fold higher hazard for all-cause mortality (34,105) and heart 
failure events can be observed in non-responder patients, it would be crucial on one hand 
to select an optimal patient population for the therapy, on the other hand to identify non-
responders in an early phase of the resynchronization and extend the optimal heart failure 
therapy or tailor to further ventricular assist device implantation or transplantation as 
appropriate. 
Regarding patient selection for CRT therapy, the assessment of QRS morphology and 
width, symptoms, ejection fraction, age, gender or co-morbidities are essential, measuring 
biomarkers might be also useful and reflect the overall status of the patient.  
In this regard, NT-proBNP is a feasible marker to stratify patients into risk categories 
(106,107) at baseline, however data are controversial on its possible predictive role in 
evaluating the response (108).   
Therefor first we aimed to assess the predictive role of baseline NT-proBNP and the 
diagnostic value of 6-month follow-up levels in identifying non-responder patients to 
CRT. In our patient cohort, baseline levels were similar in responders and non-responders, 
but 6-month NT-proBNP levels significantly decreased in responders to CRT. In line with 
the biomarker data, responders showed clear echocardiographic evidences of reverse 
remodeling (Table 2).  
Similar results were found in CARE-HF trial (109), where Fruhwald et al. demonstrated 
that CRT significantly reduces NT-proBNP levels after 3 to 6 months compared to 
optimal pharmacological treatment. The MADIT-CRT trial also suggested that baseline 





improvements; however, follow-up levels of NT-proBNP were in significant association 
with the echocardiographic response to resynchronization (108).   
In addition to NT-proBNP, a recently identified cardiac peptide, apelin has attracted 
considerable attention in chronic heart failure. Although changes in plasma apelin levels 
during the progression of heart failure, clinical trials are controversial. In one of the 
largest studies including 202 patients Chong et al. found that plasma apelin-12 (also cross-
reactive with apelin-13, -36 fragments) was significantly lower in patients with advanced 
heart failure referred for heart transplantation (47). In another study Chen et al. examined 
80 patients with moderate to severe chronic heart failure compared to healthy volunteers. 
According to their findings, circulating apelin increases in the early stage, while in 
advanced heart failure it decreases to a lower level, but remains over the normal plasma 
range (110). 
However, the role of apelin in patients after CRT is not well elucidated. To date, the only 
small-sized study which described changes in levels of apelin after CRT was published 
by Francia et al. (111). In fourteen patients undergoing CRT implantation, significant 
increase in serum apelin levels was found after 9 months of resynchronization. Evidently, 
this low sample size did not allow the authors to compare apelin in responder and non-
responder patients; the single patient considered non-responder had higher apelin level 
than the others.  
In our prospective trial including 81 patients, responders and non-responders showed the 
same CT-apelin values at baseline. However, non-responders had significantly higher 
CT-apelin levels at six months compared to responders after CRT implantation. Likewise, 
patients with high CT-apelin levels had a 10-fold higher risk for non-response. Given the 
potential collinearity between NT-proBNP and apelin, multivariate models were 
developed to determine the independent estimate of non-response. Based on such 
statistical models, apelin proved to be the independent biomarker in identifying non-
response.  
These results suggest that a simple measurement of biomarkers at baseline has limited 
impact on identifying non-responder patients, while follow-up levels may help in 
identifying them, which might come from the fact that the efficacy of resynchronization 
is influenced by multiple parameters. 
 
After the optimal patient selection, the implantation procedure is also essential. There can 





difficult to reach the wedge position. Several multicenter, randomized trials investigated 
the role of LV lead location in CRT response(112,113). The mid-term follow up of 
MADIT-CRT with 29±11 months, the LV lead position was assessed in 799 patients, 
where 71% of the patient population had typical LBBB QRS morphology and 
approximately 50% had ischemic etiology(113). Positions were categorized by short 
(anterior, lateral, or posterior) and long axis (apical vs. non-apical) positions. The 
beneficial response to cardiac resynchronization therapy was similar with short axis 
positions (P=0.652), but it was significantly better in nonapical positions compared to 
leads located in the apical region regarding the risk of heart failure events and death 
(HR=1.72, 95% CI: 1.09 to 2.71; P=0.02) after adjustment for the clinical covariates. 
REVERSE(112) trial also found similar results, thus based on these conclusive data of 
the largest, randomized trials, LV lead positioning in the apical region is associated with 
an unfavorable outcome, suggesting that this lead location should be avoided in cardiac 
resynchronization therapy.  
Extended beyond the localization, right to left ventricular activation delay, the parameter 
used in our prospective, single-center study is however a more comprehensive 
measurement providing information not only about the LV lead, but also about the RV 
lead position. Several studies have indicated that the location of the right ventricular lead 
plays a role in the clinical outcome of CRT patients (114). Furthermore, RV-LV 
activation delay may reflect slow conduction, as it is frequently seen in patients with 
ischemic heart disease and extensive scarring of the posterior or lateral wall.  
At the same time it seems that RV-LV AD may point to significant electrical 
dyssynchrony that could be a better surrogate marker for CRT benefit than mechanical 
dyssynchrony. A recent editorial suggests LBBB as an electrical disease, and CRT as a 
potent therapy for this electrical disease (115). Therefore, it is sensible that patients with 
non-LBBB did not derive a significant benefit from CRT therapy in our study, 
independently of short or long RV-LV AD at implantation. The disease process may be 
more complex in patients with non-LBBB and needs further investigations. 
Therefor we investigated the impact of RV-LV AD specified by typical LBBB 
morphology on clinical outcome in our patient cohort. Based on our results, LBBB 
patients with an RV-LV activation delay ≥86 ms have a significantly lower risk of HF or 
death and lower risk of all-cause mortality compared to those with non-LBBB ECG 
morphology combined with LBBB and RV-LV AD < 86 ms. In non-LBBB patients, RV-





has an independent role in predicting improvement in left ventricular ejection fraction, 
NT-proBNP and functional outcome in LBBB patients undergoing CRT implantation. In 
our analyses we used 86 ms as a cut-off value for RV-LV AD, the lower quartile of RV-
LV AD to predict the primary composite endpoint, which was pre-specified in our 
analysis. 
D’onofrio et al. (55,56) published similar results in 301 patients who underwent CRT 
implantation and had LBBB morphology. In this article ROC curves showed 80 ms as the 
optimal cut-off value of RV-LV AD and 65% of its normalization to QRS. Those patients 
who had greater RV-LV AD than 80ms or RV-LV AD to QRS than 65% had significantly 
better outcome in echocardiographic reverse remodeling, which was defined as >15% 
ESV change. Their results are in line with our findings, the normalization of AD to QRS 
is also a feasible parameter in selecting patients who might benefit from CRT 
implantation. Those patients who have higher RV-LV AD to QRS and LBBB 
morphology have the lowest risk for heart failure events or death. The assessment of these 
parameters have higher importance in the subgroup of patients who have narrower QRS. 
In another study by Kristiansen et al. (54), they used an RV-LV interlead sensed electrical 
delay of ≥ 85ms and showed differences in echocardiographic response and in clinical 
outcome. However, none of these studies looked specifically at sub-groups of LBBB and 
non-LBBB patients. 
Other studies used a different approach of evaluating successful resynchronization with 
CRT. Gold and colleagues (116) were focusing on the association of clinical outcome and 
ventricular electrical delay measured by Q-LV in 426 patients with advanced heart 
failure, measuring LV lead activation time from the beginning of the QRS. Similarly to 
our results they found significant differences in functional parameters such as end-
systolic volume reduction and quality of life improvement 6 months after CRT 
implantation in those patients who had a greater Q-LV time than the median of 95 ms.  
Our prospective trial is in line with several previous studies (69,117,118) suggesting that 
best response to cardiac resynchronisation therapy is achieved in patients with a "left 
bundle branch block cardiomyopathy" with optimal positioning of the left ventricular 
lead. However to our knowledge, this is one of the first studies evaluating the effect of 
RV-LV activation delay in patients undergoing CRT by their baseline LBBB ECG 
pattern. Some of the previous studies adjusted the multivariate models for LBBB, but 
there were no pre-specified sub-group analysis performed in patients with a baseline 





Moreover, in our prospective, single-center study the beneficial clinical outcome was 
reflected in the decrease of prerenal dysfunction, independently of the baseline renal 
function values. In patients with longer RV-LV AD and LBBB morphology, serum 
creatinine and BUN values were significantly lower than in those with shorter RV-LV 
AD or non-LBBB ECG morphology at six month follow up.  
Several trials assessed impaired renal function as a potential independent risk factor of 
mortality and morbidity in chronic heart failure (119,120). The markers of prerenal 
dysfunction were also discussed in mildly symptomatic patients (121) and in advanced 
heart failure (122) after resynchronization.  
In an early study of MIRACLE(122), 453 severe heart failure patients (228 CRT vs. 225 
control) with symptoms (NYHA III-IV), low ejection fraction (LVEF≤ 35%) and wide 
QRS (≥130ms) were investigated. They were categorized according to their baseline 
eGFR (≥ 90; 60-89; 30-59) and changes of 6-months levels were assessed. Patient group 
with GFR<30 was excluded from analyses due to the low number of investigated patients. 
However no data was shown about the amount of LBBB patients in this study, their results 
showed, CRT improved LV function in all categories, but the most prominent 
improvement of GFR was observed in patients with GFR<60 compared to control group 
(−2.4±1.2 vs. +2.7±1.2 mL/ min per 1.73 m2; p=0.003). These early results underscored 
the importance of cardiorenal interaction and the beneficial effects of CRT which 
indirectly improve renal function. The association of RV-LV AD and the changes of renal 
function have not been directly investigated before, our results show first, that the 
improvement in renal function might be more pronounced when the most eligible patients 
are selected: those with LBBB and a longer RV-LV AD. 
 
6.2 Part 2 - The question of CRT upgrade 
As discussed above, several high volume, multicenter, randomized trials investigated 
extensively the effect of de novo CRT implantation, provided comprehensive data and 
clear evidences for patients with chronic heart failure.  
Besides recommendations on CRT upgrades are still ambiguous, although biventricular 
upgrade affects roughly 5-10% of patients who undergo prior ICD or pacemaker 
implantation (123,124). The evidences are partly extended over time, however still not 





The 2013 ESC/EHRA guidelines recommend CRT upgrade in patients with LVEF < 
35%, NYHA III-IVa and high percentage of ventricular pacing – although the cited 
evidence stands for de novo CRT implantations and crossover trials as opposed to 
upgrades from existing devices, with level of evidence “B” and class I indication (125). 
The 2012 ACCF/AHA/HRS guidelines are listing CRT upgrade with IIa indication, level 
of evidence “C” for patients with LVEF ≤ 35%, and a need for at least 40% ventricular 
pacing, for both new implants and device replacements (126). The 2012 ESC/HFA 
guidelines (127), the 2013 Appropriate Use Criteria (AUC) document, endorsed by the 
ACCF/HRS/AHA,(128) and the most recent 2015 ESC/EHRA Guideline on ventricular 
arrhythmias and sudden cardiac death do not provide any recommendations on CRT 







Table 15. Indication for upgrade to cardiac resynchronization therapy in patients with 
existing pacemaker or ICD 
ESC/EHRA 2013 
(125) 
CRT is indicated in HF patients with LVEF 
<35% and high percentage of ventricular 
pacing who remain in NYHA class III and 
ambulatory IV despite adequate medical 
treatment. 
Remark: Patients should generally not be 
implanted during admission for acute 
decompensated HF. In such patients, 
guideline-indicated medical treatment should 
be optimized and the patient reviewed as an 
out-patient after stabilization. It is recognized 





CRT can be useful for patients on GDMT who 
have LVEF less 
than or equal to 35% and are undergoing new 
or replacement 
device placement with anticipated 
requirement for significant 





CRT is recommended as an alternative to 
conventional right ventricular pacing in 
patients with HF-REF who have a standard 
indication for pacing or who require a 




for CRT upgrade 
AHA= American Heart Association; ACCF= American College of Cardiology 
Foundation; CRT= Cardiac Resynchronization Therapy; EHRA= European Heart 
Rhythm Association; ESC= European Society of Cardiology; GDMT= Guideline 
Determined Medical Therapy; HFA= Heart Failure Association; HF-REF= Heart Failure 
with Reduced Ejection Fraction; HRS: Heart Rhythm Society; LOE= Level Of Evidence; 





These recommendations are based on trials with design of RV pacing vs. CRT upgrade 
and non-randomized, observational prospective “upgrade vs. de novo” studies, which are 
included in the our meta-analysis (87,89,90,95,101) and which will be discussed in 
details. In addition, there are small observational retrospective (130-136) and cross-over 
(137-140) trials with a low number of patients. 
 
The harmful effect of chronic RV pacing and inferiority to biventricular pacing revealed 
from early large randomized studies.  
Regarding the association of frequent RV pacing and adverse clinical outcomes, several 
trials confirmed an increased risk of heart failure events, atrial fibrillation and all-cause 
mortality (125,141).  
The Dual-Chamber and VVI Implantable Defibrillator (DAVID) trial demonstrated 
worse outcomes in patients with reduced LVEF and dual chamber ICD programming to 
DDDR 70 bpm when compared to patients with VVI 40 bpm pacing. Every 10% increase 
in RV pacing increased the risk of death or HF hospitalization by 16%. The most 
significant separation was observed with 40% RV pacing, strongly predicting death or 
HF hospitalization (HR=5.2, P=0.008) (142).  
Another multicenter, randomized clinical trial, the Mode Selection Trial (MOST) 
confirmed the correlation of RV pacing and impaired clinical outcome in patients with 
preserved LVEF and sinus node dysfunction. The risk of HF hospitalization linearly 
increased with RV pacing up to 40% (141).  
In contrast, Olshansky et al. suggested that reducing RV pacing does not necessarily 
eliminate the risk of an adverse outcome. In the INTRINSIC RV Study patients were 
categorized into six groups based on increasing RV pacing rates. A significant difference 
was found between rates concerning patients’ age, history of ventricular tachycardia, 
atrial fibrillation, atrial flutter, and amiodarone therapy. Adjusting for these parameters, 
the best outcome was seen in patients with RV pacing between 10-19% (2.8% event rate 
over a median follow up of 11.6 months). Increasing RV pacing has been found predictive 
of death or HF hospitalization (p=0.003). Other than expected, patients with rare RV 
pacing (0–9%) experienced worse outcome (8.1% event rate, p=0.016), although a lower 
RV pacing rate may be advantageous to improve AV dyssynchrony (143).  
In addition, echocardiographic and functional parameters (6-minute walk test, symptoms) 
may also worsen even in patients with previously preserved ejection fraction(144,145) or 






Thus due to the RV pacing-induced dyssynchrony, patients with a high percentage of RV 
pacing are at high risk of adverse clinical outcomes (71,72) and  can become candidates 
for CRT upgrade. Based on these findings, several trials focused on patients with RV vs. 
biventricular pacing and confirmed the superiority of CRT upgrade in this patient 
population. 
First small crossover trials have compared RV pacing only to CRT in patients with 
symptomatic bradycardia and reduced LVEF. They showed that CRT reduced mortality, 
heart failure hospitalization and lead to reverse ventricular remodeling (125,147).  
Then for the first time, the Biventricular versus Right Ventricular Pacing in Heart Failure 
Patients with Atrioventricular Block Trial (BLOCK HF) showed that CRT is superior to 
RV pacing in patients with AV block, LVEF ≤ 50% and heart failure class NYHA I-III. 
After a median follow-up of 37 months, primary endpoints (death from any cause, heart 
failure visit that required intravenous therapy, or ≥15% increase in LVESV index) 
occurred in 190 of 342 patients (55.6%) in the RV pacing group, compared with 160 of 
349 (45.8%) in the CRT group. The LV lead related complications occurred in 6.4% of 
the patients in the CRT treated group.(146) 
The Homburg Biventricular Pacing Evaluation (HOBIPACE) trial compared CRT to RV 
pacing in patients with bradycardia and LV dysfunction (LV end-diastolic diameter ≥ 60 
mm and LVEF ≤40%). Three months of RV pacing vs. biventricular pacing were studied 
in 30 patients. Improved echocardiographic parameters- laboratory values and quality of 
life scores, as well as improved peak exercise capacity were found only with biventricular 
pacing. (148) 
The Conventional versus Multisite Pacing for BradyArrhythmia Therapy crossover Study 
(COMBAT) compared biventricular versus right ventricular pacing in 60 patients with 
AV block, LVEF <40 % and heart failure with NYHA class II-IV. After a follow-up of 
17.5 months the quality of life, NYHA class and echocardiographic parameters improved 
in patients with CRT. Overall mortality was significantly higher in patients with RV 
pacing alone (86.7% vs. 13.3%, p=0.012)(147). Studies performed in patients with 
preserved LVEF also demonstrated benefit with CRT, showing increased reverse LV 
remodeling.  
The Long term from the Pacing to Avoid Cardiac Enlargement (PACE) trial investigated 
the clinical outcomes of 149 patients with CRT with the mean EF of approximately 62% 





RV or biventricular pacing after an extended follow-up of five years (mean 4.8 ± 1.5 
years). In the RV pacing group, LVEF and LVESV worsened progressively during 1-
year, 2-year, and long-term follow-up, whereas both parameters remained unchanged in 
the CRT group (LVEF difference respectively p<0.001). However, patients with RV 
pacing needed significantly more HF hospitalization (23.9%) than CRT patients 
(14.6%)(149). In summary, chronic biventricular pacing seems to be superior to RV only 
pacing, but the results cannot be extrapolated to patients with intermittent or chronic 
pacing who developed worsening of heart failure only recently. 
The RD-CHF study upgraded 56 patients from VVI pacing (NYHA III-IV, and LV 
dyssynchrony) to CRT at the time of generator replacement. The study had a three month 
cross-over design with RV pacing only or CRT. CRT pacing significantly improved 
NYHA class, 6MWT and quality of life (125).  
 
Regarding the study design of trials referred in the current ESC recommendations, the 
last and at the same time, the largest group came from the non-randomized, observational 
prospective “upgrade vs. de novo” studies (87,89,90,95,101).  
The only trial, in which patient groups were analysed retrospectively came from the 
Resynchronization–Defibrillation for Ambulatory Heart Failure Trial (RAFT) study. In 
RAFT 644 of 1346 enrolled patients (48%) underwent de novo CRT implantation, 80 
patients were upgraded to CRT from a previously implanted ICD device, and 60 patients 
underwent CRT upgrade 6 months after the end of the initial study.  
The success rate was 95.2% for de novo, 96.3% for upgrade and 90.0% for post-trial CRT 
upgrade sub-study (p=0.402). The acute complication rate was 26.2% for de novo, 18.8% 
for upgrade and 3.4% for the sub-study CRT upgrade (p <0.001), most commonly due to 
LV lead dislodgement. The main reasons for not attempting upgrade in the sub-study 
group were patient preference (31.9%), NYHA class I (17.0%), and QRS<150 ms 
(13.1%).  
The authors conclude that the success of CRT upgrade is high and that the complication 
rates are similar to de novo CRT implantation (150). However, in the prospective 
REPLACE Registry with 1750 patients undergoing device replacement, those who 
required upgrade experienced a high rate of major complications during a 6-month 
follow-up time (18% vs. only 4%).  
While there are no randomized trials with such design, we decided to perform a 





or upgrade CRT implantations. Our meta-analyses revealed no significant difference in 
all-cause mortality between the two patient groups. Also, no significant differences were 
found in changes of echocardiographic parameters of reverse remodeling (EF, EDV). 
Functional changes (i.e. improvement of NYHA functional class) and narrowing of QRS 
were also similar, suggesting that adding left ventricular pacing in patients with prior 
cardiac devices may be a safe and feasible procedure that may result in similar clinical 
benefits as de novo implantations.  
In most of these trials, only soft endpoints, such as NYHA functional class, 6-minute 
walk test, quality of life or echocardiographic parameters were analyzed. Summarizing 
the most frequently investigated clinical parameters, such as change in NYHA functional 
class, decrease in QRS duration, changes of left ventricular ejection fraction and end-
diastolic volume, no significant differences were observed between the de novo and 
upgrade groups in our analysis.  
The only outcome that showed a significant difference is the risk of heart failure events 
that was more common in the de novo group as compared to patients with upgrade 
therapy. However, this difference should be interpreted cautiously due to the non-
randomized, non-adjusted design and limited number of reporting studies.  
Data regarding long-term mortality were reported only in a few prior 
trials(87,89,91,93,94,98,100,102). The largest report from these was the European 
Cardiac Resynchronization Survey(87) comprising 1489 de novo and 601 upgrade CRT 
patients from 2011. Total mortality at 1 year was low and similar in both groups (8.6% 
vs. 7.9%, p=0.57). Although this registry showed representative data about mortality rates 
with high number of enrolled patients, there are a huge number of potential confounders 
that may have biased the overall results.  
Therefore, trials with adjusted analyses are essential to control baseline differences to 
better assess the effects of CRT upgrade on long-term survival. In the current meta-
analysis, three observational studies with adjusted all-cause mortality endpoints were 
included.  
Tayal et al (102) compared 85 patients who underwent de novo CRT implantation and 50 
patients with CRT upgrade. During the 4 years of follow-up time, patients with prior right 
ventricular pacing had a significantly lower risk of fatal events than patients with de novo 
CRT implantation (adjusted HR 0.25, 95% CI 0.07-0.88, P= 0.03).  
Gage  et al. (91) compared 190 patients with prior high percentage of right ventricular 





median follow up of 4.2 years, upgrade patients tended to have better outcomes in terms 
of all-cause mortality (adjusted HR 0.73; 95% CI 0.53-1.01; p=0.055).  
In contrast, Vamos et al. (103) recently reported a higher risk for mortality in the upgrade 
group when compared to de novo implantation in 552 patients. In this multicenter study 
with a mean follow up of 37 months, patients who underwent CRT upgrade had a 
significantly higher risk of all-cause mortality compared to patients with de novo 
implantations even after adjusting for potential confounders with multivariate Cox 
regression analysis (adjusted HR 1.68, 95% CI 1.20-2.34, p=0.002) and after applying 
propensity score matching (PS-adjusted HR 1.79, 95% CI 1.08-2.95, p=0.023).  
Summarizing all these results in our meta-analysis, a similar long-term survival was 
found between the two patient groups. However, heterogeneities in the results of adjusted 
studies largely emphasize that randomized controlled trials are needed to objectively 
clarify this clinical dilemma.  
Despite the current detailed review and meta-analysis of the available clinical evidence, 
several questions remain unanswered. Most striking from these include which 
populations may derive the largest benefits from upgrading and what is the optimal timing 
for such procedures. 
According to these lines of evidences and considerations it seems reasonable upgrading 
to CRT in HF patients with previously implanted cardiac devices and a high percentage 
of right ventricular pacing. On the other hand, upgrade procedures may be associated with 
higher surgical risk, such as venous access issues, the risk of damage or extraction of 
previously implanted leads, higher infection rates, and longer procedure times (123,151), 
that all together may significantly compromise the success of LV pacing.  
It should be also noted, that etiology or the cause of decreased ejection fraction might be 
different in upgrade vs. de novo CRT groups. Regarding the etiology, similar percentage 
of ischemic and non-ischemic heart disease were reported in most of the included studies, 
however the baseline QRS was wider (paced QRS) and patients were older and had atrial 
fibrillation more often in the upgrade group.  
To conclude there was a clear need for a large, randomized trial on this field, thus we 
initialized the BUDAPEST CRT upgrade study, the first, multicenter, randomized, 
investigator-initiated trial, which clarifies the question of CRT upgrade.  
In the BUDAPEST CRT upgrade study patients with previously implanted PM or ICD 
devices, symptomatic heart failure (NYHA II-IVa), reduced ejection fraction (≤ 35%) and 





randomized to CRT-D or ICD in a 3:2 manner.  
When the design of the trial was prepared by the PI’s and members of the Steering 
Committee, the inclusion and exclusion criteria were discussed in details. We would 
include patients regardless of heart failure etiology with no prior acute events in the last 
three months prior to enrolment and as required in clinical studies we would like to 
exclude those factors that could influence the final results and patient’s response such as 
e.g. genetic disorders, those parameters lead to high numbers of lost-to follow up or 
severe diseases that are waiting for procedures or co-morbidities with a specific regard to 
renal insufficiency or dilated right ventricle (Table 1).  
In the inclusion criteria, the cut off value for left ventricular ejection fraction was defined 
as 35% or less, while most of the previously discussed trials and evidences for CRT 
showed a clear benefit in this patient population.  However the BLOCK-HF which 
included patients with preserved ejection fraction (total mean EF 40 ± 8%),  also showed 
superiority of biventricular pacing compared to right ventricular pacing in a large, 
randomized study, but patients had less severe symptoms (NYHA I-III) and III. degree 
AV-block, which is not exactly the same patient population, that we would like to 
investigate.  
In exclusion criteria intrinsic LBBB morphology was crucial, while evidences are also 
comprehensive in this regard, such patients are need to be upgraded. 
To define the cut off value of the rate of right ventricular pacing for inclusion citeria was 
also essential during the preparation. While the previously described MOST(71) trial 
provided the highest risk for adverse events at 40% of DDD pacing, and at the same time 
in DAVID trial (72) each 10% higher pacing related to 16% increase in the risk of heart 
failure events and death, we decided to have a 20% pacing or higher for inclusion criteria 
in order to cover also the grey zone of 20-40%, which is actually missing from the 
American and European guidelines. 
The primary endpoints are the composite of heart failure events, all-cause mortality and 
echocardiographic increase of ESV>15% after 12 months. As this criteria also occurred 
at the BLOCK-HF trial, we would investigate together the tough endpoints (heart failure 
and all-cause mortality) and echocardioghraphic response as well. 
It was also a special point of view during design preparation to encourage sites to follow 
their every-day clinical practice, therefor physicians are allowed to perform lead 






Regarding the current status of the BUDAPEST CRT upgrade study, 31% of the planned 
total patient number have been already enrolled from 26 centers (20 European: Hungary, 
Czech Republic, Germany Poland, Russia, Serbia and Slovenia and 6 Israeli sites). Where 
the Semmelweis University included approximately 60% of patients as the top enroller.  
Our preliminary data about baseline clinical characteristics show similar results as the 
patient cohorts in the literature in regards of mean age, mean left ventricular ejection 
fraction or gender. However it is early to discuss the question of endpoints or adverse 
events, at this time we have more heart failure events on ICD arm, while no significant 
number of complications can be occurred. 
In summary the BUDAPEST CRT upgrade study would be a milestone on the field of 




Our prospective single-center study has some certain limitations. First, this was a 
relatively small registry-based patient cohort with low rate of endpoint events that may 
result in overestimating our results. 
Notably, this is still the largest dataset among patients after CRT implantation with apelin 
level assessments at a relatively long (3-year) follow-up.  
Second, the observed plasma levels of CT-apelin in our study were considerably higher 
than found in other prior studies.(46,48) This may be due to the various sensitivities of 
the assays for different apelin fragments, making it difficult to directly compare results. 
By using RayBiotech C-Terminus-apelin ELISA kit we have detected apelin -36, -13, -
28 and -31 fragments, that might be responsible for the differences compared to other 
authors that usually detected only the apelin -12, -13, -36 fragments by another 
commercially available ELISA kit.(48,110,111)  
Finally, the 3-year rate of cardiovascular mortality may sound quite low in the present 
study compared to other experiences. (13,14) However, we only included patients with 
successful device implantation and having 6-months biomarker laboratory results 
available. Therefore, our results may reflect a lower-risk cohort with successful device 
implantation and without mortality within the first 6 months of CRT operation.  
Regarding RV-LV AD measuring, it may have been influenced by baseline QRS duration 





adjusted our models for QRS duration and our results were similar. Furthermore, suitable 
vein distribution for LV lead implantation is a known bias for all CRT studies and 
therefore needs to be acknowledged. Alternatively, minimal invasive techniques eg. mini-
thoracotomy LV lead implantation (152) or transseptal LV endocardial pacing could have 
been used to further maximize RV-LV AD and optimize CRT outcome. However such 
methods have not become widely used in the past due to the relative invasive nature of 
the procedure.  
Regarding our meta-analysis patients in the two groups were not randomly allocated, all 
included studies were either retrospective studies with historical controls or prospective 
observational data collections. Furthermore we did not have access to individual patient-
level data precluding us from calculating adjusted hazard ratios for all the included 
studies. Finally, the length of follow-up was also heterogeneous in the included reports. 
However, so far, this is the largest available comprehensive evidence in this respect and 









Cardiac resynchronization is an effective device therapy, while improve cardiac function, 
symptoms and reduce the risk of hospitalization and all-cause mortality in patients with 
mild to severe heart failure and a prolonged QRS (13-15). However there have been still 
a large amount of patients who could not show a beneficial response after CRT 
implantation.  
Thus in our prospective, single-center study which was implemented from Semmelweis 
University, Heart and Vascular Center - our high-volume experienced clinic, those 
parameters which could influence or predict the response to CRT were investigated in 
regard of optimal patient selection and intraoperative parameters.  
 
In our cohort less than 20% of heart failure patients failed to develop reverse remodeling 
and became non-responders to resynchronization, showing an elevated risk for all-cause 
mortality compared to responders.  
However resynchronization therapy proved to be the most beneficial non-
pharmacological treatment, selection of these vulnerable patients is essential in order to 
extend the heart failure therapy or tailoring forward to definitive therapy as heart 
transplantation or ventricular assist device. 
Our results showed, baseline levels of biomarkers: CT-apelin and NT-proBNP were not 
associated with non-response. Therefore, these biomarkers are ineligible as predictors of 
success before device implantation. However when six-month levels of both CT-apelin 
and NT-proBNP were investigated, a significant association with non-response was found, 
suggesting the possible role of such biomarkers in identifying high risk patients, where 
CT-apelin showed the superiority over NT-proBNP.  
These findings are rational, while the response to CRT is multifactorial, but these 
biomarkers may give additional information to define non-responders assigning the most 
vulnerable patients. 
 
In those patients having typical LBBB morphology, where the largest benefit is expected, 
there are further factors, that might help optimizing the effect of CRT. 
The intraoperative right to left ventricular activation delay, which reflects not only the  





and prolonged activation pattern derived from the slow conduction, had a predictive value 
for the outcome.  
Our results showed, in LBBB patients with a longer or equal to 86 ms right to left 
ventricular activation delay, a significantly lower risk of composite of heart failure events 
and death occured and lower risk of all-cause mortality alone compared to those with 
non-LBBB or those with LBBB and shorter than 86ms right to left ventricular activation 
delay. Moreover our results show that right to left ventricular activation delay predicts 
the improvement in left ventricular ejection fraction, NT-proBNP and functional outcome 
in LBBB patients. Thus simple assessment of intraventricular right to left ventricular 
activation delay could tailor the procedure to achieve the optimal position with a longer 
activation delay. 
 
Despite having conclusive data about those patients who are eligible for de novo CRT 
implantation, there is still a lack of evidences and recommendations for CRT upgrade in 
the current ESC guidelines, however approximately 10% of patients who are referred for 
the procedure underwent conventional pacemaker or ICD implantation before.  
We summarized the currently available data from the literature with 17 studies and more 
than 6600 patients, who underwent de novo or upgrade CRT implantations. Concluding 
our results, patients after CRT upgrade from conventional pacemakers or ICDs show 
similarly beneficial response compared to de novo CRT implantation regarding all-cause 
mortality or clinical outcome such as echocardiographic reverse remodeling or functional 
outcome. Despite the more complex upgrading procedure, the risk of adverse events also 
seems comparable. Our results suggest that CRT upgrade may be safely and effectively 
offered to patients in routine clinical practice. These are the first results which will be 
released from a prospective multicenter randomized clinical trial, the BUDAPEST-CRT 
upgrade study, which will provide conclusive data on the effects of upgrade procedures 
in patients with previously implanted pacemaker or ICD devices, reduced LVEF ≤ 35%, 
symptomatic heart failure (NYHA-II-IVa), and intermittent or permanent right 







Our results can be summarized in a point by point manner as follows: 
 
 In our patient cohort 20% of heart failure patients failed to develop reverse 
remodeling 
 A simple cross-sectional value of gold-standard NT-proBNP or CT-apelin 
could not predict the outcome, but serum levels after 6 months were 
significant indicators of non-response 
 In this regard 6-months apelin level was superior compared to NT-proBNP 
 From intraoperative parameters, assessment of RV-LV AD could predict 
the outcome in patients with typical LBBB morphology 
 Patients with longer than 86ms LV-RV AD was associated with a better 
improvement of ejection fraction, NT-proBNP, and with better HF-free 
survival and overall survival 
 But not in those with a shorter RV-LV activation delay, or in those with a 
non-LBBB morphology 
 Concluding the currently available data, our meta-analysis suggests that 
patients undergoing CRT upgrade show similarly beneficial response 
compared to de novo CRT implantation regarding all-cause mortality or 
clinical outcome such as echocardiographic reverse remodeling or 
functional outcome. 
 The BUDAPEST CRT upgrade study is the first investigator-initiated, 
multicenter, randmized trial from Semmelweis University, which will 








Cardiac resynchronization is an effective device therapy of chronic heart failure, however 
there have been still a large amount of non-responder patients and those for whom the 
current guidelines do not provide clear recommendations such as patients with an already 
implanted device. 
Thus first we aimed to evaluate those parameters which could predict or influence the 
response to de novo CRT implantation in regard of optimal patients selection - with 
assessment of serum biomarkers such as CT-apelin and NT-proBNP - and an 
intraoperative parameter, the right to left ventricular ativation delay specified by QRS 
morphology. Second we described the clinical response of patients with an already 
implanted pacemaker or implantable cardioverter defibrillator who underwent CRT 
upgrade. 
In our single center, prospective study, 125 patients were registered who underwent CRT 
implantation as per current guidelines and followed for two years. Baseline and 6-month 
clinical parameters, laboratory tests, serum biomarkers, echocardiographic parameters 
were assessed, while right to left ventricular delay was measured at implantation. 
Regarding CRT upgrade, a meta-analysis was performed from all available data in the 
literature with de novo vs. upgrade CRT implantation.  
Based on our results 20% of patients proved to be non-responders. Serum biomarkers at 
baseline could not predict and select such patients, but serum levels after 6 months were 
feasible in identifying non-responders, where 6-months apelin level was superior 
compared to NT-proBNP.  
When right to left ventricular delay was assessed, it was an independent predictor of heart 
failure events and all-cause mortality in patients with LBBB and longer activation delay 
but not in those with nonLBBB or short activation delay. Patients with LBBB and long 
activation delay had also the greatest clinical improvement in ejection fraction, NT-
proBNP, renal function and 6-minute walk test. 
Our meta-analyses of upgrade vs. de novo CRT implantation revealed no significant 
differences can be observed between the two groups in all-cause mortality, changes of 
echocardiographic or functional parameters and QRS narrowing suggesting this is a safe 
and effective therapy of patients with a previously implanted device. 
However this question will be clarified by the BUDAPEST CRT upgrade study, a 







A kardiális reszinkronizációs terápia hatékony eszközös kezelés szisztolés 
szívelégtelenségben, azonban a terápiára kevéssé reagáló non-responder betegek aránya 
még mindig igen magas, illetve az aktuális ajánlások hiányosak azon betegek 
reszinkronizációs kezelése, CRT upgrade-je tekintetében, akik már rendelkeznek 
konvencionális pacemakerrel vagy beültethetõ cardioverter defibrillátorral. 
Kutatásunk célja olyan paraméterek vizsgálata volt, amelyek befolyásolják vagy elõre 
jelzik a CRT-re adott válaszkészséget. Az optimális betegszelekció tekintetében 
vizsgáltuk a serum biomarker-szintek, mint az NT-proBNP és CT-apelin változását és 
prediktív szerepét, illetve az intraoperativan mérhetõ kettősjeltávolság hatását QRS 
morfológia szerint. Emellett összefoglaltuk az irodalomban elérhetõ összes, a CRT 
upgrade-re vonatkozó eredményeket. 
Egy-centrumos, prospektív vizsgálatunkban 125 beteg esett át CRT implantáción az 
aktuális ajánlásoknak megfelelõen. A beválasztáskori és 6 hónappal az implantáció után 
végzett klinikai értékeket regisztráltuk, így a laboratóriumi, funkcionális, serum 
biomarker és echocardiographiás paramétereket, valamint implantáció során a kettősjel 
távolságot. A betegeket 2 évig követtük. Emellett CRT upgrade témájában végzett meta-
analízisünkben az upgrade-en átesett betegeket a de novo implantáción átesett betegek 
klinikai kimeneteléhez hasonlítottuk. 
Az általunk vizsgált betegcsoportban 20% bizonyult non-respondernek. A beválasztáskor 
mért serum biomarker szintek nem voltak alkalmasak ezen betegek kiválasztására, 
azonban a hat hónappal késõbb mért szintek kijelölték a non-reponder betegcsoportot, 
amelyben a CT-apelin hatékonyabbnak bizonyult az NT-proBNP-hez képest. A kettősjel 
távolság vizsgálata során, az a mortalitás és a szívelégtelenség esemény független 
prediktív faktorának bizonyult bal-szárblokkos és hosszabb jeltávolsággal rendelkező 
betegekben. Ugyancsak ezen betegek mutatták a legnagyobb klinikai javulást az 
echocardiographiás válasz, az NT-proBNP, a vesefunkció és a 6-perces járásteszt 
tekintetében.  
Meta-analízisünk alapján nincs különbség az össz-mortalitás, echocardiográphiás vagy 
funkcionális válasz illetve a QRS szélesség változásának tekintetében, amely eredmények 
szerint az upgrade biztonságos és hatékony eljárás. Mindezt azonban a multicentrikus, 
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